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Infection by oncogenic human papillomavirus (HPV) is known to be the causative agent for 
the development of various anogenital cancers, including cervical cancer. Worldwide, the 
majority of cervical cancer cases occur in less developed regions, and while prophylactic 
vaccines exist to combat HPV infection, they are largely unattainable in these areas. 
Therefore, alternative preventative measures against HPV infection are needed to help 
eradicate cervical cancer over time. Since HPV employs multiple mechanisms to evade the 
host immune response, a proposed method for preventing infection may be by enhancing 
HPV recognition by the immune system. Surfactant proteins A and D (SP-A and SP-D) are 
innate immune proteins with a variety of functions including recognition and opsonisation of 
pathogens. They are primarily found in the lung, but have also been shown to be expressed 
at other sites of the body, including the female reproductive tract. It was hypothesised that 
SP-A and/or SP-D may enhance immune recognition of HPV, thereby preventing infection. To 
assess this hypothesis, co-immunoprecipitation and flow cytometry experiments were 
performed to determine whether SP-A and/or SP-D bind to HPV16 pseudovirions (HPV16-
PsVs). SP-A was shown to bind to HPV16-PsVs as well as enhance viral uptake by RAW264.7 
murine macrophages, while SP-D bound HPV16-PsVs weakly and had no effect on viral 
uptake. To confirm these observations and to assess whether SP-A had an effect on HPV16-
PsVs infection in vivo, a well-established, but not yet available murine HPV16-PsVs 
cervicovaginal challenge model system was set up at UCT. It was determined that neither 
naïve nor C57BL/6 mice challenged with HPV16-PsVs expressed SP-A in the female genital 
tract. However, under the experimental conditions established herein, pre-incubation of 
HPV16-PsVs with purified SP-A at a 1:10 weight per weight ratio resulted in a reduction in 
infection. This study is the first to describe a biochemical and functional association of HPV16 
virions with the innate immune molecule SP-A. In the long term, these observations may 
contribute to the development of topical microbicides incorporating recombinant fragments 






1.1. Human papillomavirus and cervical cancer 
 
Human papillomavirus (HPV) is known to be the most common viral infection of the 
reproductive tract [1,2]. There are over 180 different HPV types, which can be classified 
as either low-risk or high-risk depending on their ability to cause malignant cell 
transformation [3]. Low-risk HPV types are known to cause low-grade benign lesions or 
warts, whereas high-risk (oncogenic) types are associated with multiple carcinomas 
including head and neck cancers and anogenital cancers  [4]. It is estimated that 
approximately 5% of all human cancers are caused by HPV [5]. Most notably, virtually all 
cervical cancer cases can be attributed to high-risk HPV infection, and the predominant 
HPV types associated with cervical cancer are HPV16 and HPV18 [6]. Together, HPV16 and 
18 account for over 70% of cervical cancer cases [1,6]. However, infection with high-risk 
HPV is necessary, but not sufficient for the development of cervical cancer [7]. Other co-
factors, such as chronic inflammation and immunosuppression, facilitate cancer 
development [7], as outlined in more detail below.  
Worldwide, cervical cancer is the fourth most common cancer in women [8]. The disease 
is substantially more prevalent in developing countries as compared to developed 
countries, with 84.3% of cases occurring in less developed regions (Figure 1.1.A.) [8]. In 
South Africa, cervical cancer is the second most common cancer in women and is the 
leading cause of female cancer-associated deaths (Figure 1.1.B.) [8,9]. Since cervical 
cancer is nearly always caused by oncogenic HPV infection, it is a cancer which is 
potentially totally preventable. Highly efficient prophylactic vaccines against the most 
common oncogenic HPV types are available (described in section 1.1.4.). Additionally, 
early detection of pre-malignant or abnormal cells is possible with cervical cytology 
screening, allowing for early treatment and prevention of development of cervical cancer. 
Unfortunately, vaccination and screening programs have been difficult to establish in 
developing countries, which quite likely explains why these countries have the highest 
burden of cervical cancer [10]. Developing countries are also highly burdened by the 
human immunodeficiency virus (HIV)/AIDS epidemic, a disease known to cause 
immunosuppression. HIV and HPV co-infection is common due to shared routes of 
transmission, and HIV infection increases HPV persistence and the relative risk of cancer 
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development as compared to HPV infection alone [11,12]. This is likely due to the low 
CD4+ cell count observed in HIV-positive individuals, making HPV clearance less efficient 
which may result in HPV persistence and cancer development [13].  
 
 
Figure 1.1: Cervical cancer is a disease of the developing world. A) Incidence of cervical cancer worldwide 
in 2012, displayed as estimated age-standardized rates. B) Leading causes of female cancer-associated 
deaths worldwide in 2012. Data retrieved from GLOBOCAN and displayed using CANCER TODAY [8].  
4 
 
1.1.1. HPV genome and structure 
 
HPV is a non-enveloped, double stranded DNA virus [14]. The HPV genome is 
approximately 8000 base pairs and encodes for “early” and “late” genes (Figure 1.2.A.) 
[14].  The early genes code for E1, E2, E4, E5, E6 and E7 proteins. E1 and E2 are involved 
in replication and transcriptional regulation and E4 has a role in viral particle release [5]. 
Although the role of E5 is not well-characterised, it has been implicated in immune 
evasion (see section 1.1.3.) [5]. E6 and E7 have important roles in the viral life cycle of 
both high- and low-risk HPVs, such as episomal maintenance [15,16]. In high-risk HPV 
types, E6 and E7 also function as oncoproteins ensuring viral replication and persistence 
and thereby potentially influencing many cancer hallmarks [7]. E6 binds the central 
tumour suppressor protein p53 and marks it for degradation, therefore preventing p53 
from arresting the cell cycle during cellular stress [17]. E7 binds retinoblastoma proteins, 
thereby preventing them from modulating the function of the transcription factor E2F, 
which augments entry of cells into synthesis phase (S phase) of the cell cycle and results 
in increased cellular proliferation [17]. The combinatory result of these events overrides 
cell cycle checkpoints and allows for viral DNA replication to continue as the cell is 
maintained in S phase [5]. In addition to these functions, E6 and E7 have a role in immune 
evasion (section 1.1.3). 
The late genes code for the major (L1) and minor (L2) capsid proteins. The L1 protein can 
self-assemble into icosahedral virus-like particles, and the L2 protein seems to have a vital 
role in the establishment of infection [18]. The capsid is formed by 360 L1 proteins which 
organise into 72 pentamers, as well as approximately 30 L2 proteins which are mostly 






Figure 1.2: HPV genome organisation and viral structure. A) The HPV genome is organised into two distinct 
sets of genes, the early (blue) and late (green) genes. B) The viral DNA is harboured by an icosahedral capsid 
formed by the major L1 and minor L2 proteins. Figure adapted from [5]. 
 
1.1.2. HPV infectious cycle and malignant transformation  
 
HPV is transmitted via direct skin-to-skin contact rather than through body fluids.  As the 
virus’ life cycle is exclusively intraepithelial and closely linked to keratinocyte 
differentiation, HPV needs to infect mitotically active basal cells of the host’s cutaneous 
and mucosal epithelia that have been exposed due to microabrasions. During the early 
attachment steps, the virus binds to heparan sulphate proteoglycans (HSPGs) on the 
epithelial basement membrane or cell surface, via the L1 capsid protein [21,22]. Laminin-
332 that is secreted onto the extracellular matrix by keratinocytes can also be bound by 
HPV transiently [23]. This initial binding is thought to result in a conformational change of 
the capsid which facilitates L1 cleavage by the serine protease kallikrein-8 [24]. Following 
this, viral interaction with the host chaperone protein cyclophilin B results  in exposure of 
the N-terminus of the L2 protein [25]. This N-terminus of L2 contains a conserved cleavage 
site for the proprotein convertase furin, and cleavage by furin is believed to be essential 
for endosomal escape at a later stage of infection rather than at the early stages of binding 
and entry [26]. After conformational changes of the capsid, the virus loses affinity to 
HSPGs and binds to a still unknown entry receptor [27]. Following entry, HPV is trafficked 
through the endosomal system [28]. This occurs by HPV interacting with sorting nexin 17 
in the endosome, as well as with gamma secretase in the Golgi apparatus and endoplasmic 
reticulum [29,30]. This occurs 2-3 hours post entry [28]. After 12 hours, viral uncoating 
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occurs in the late endosome, and the viral genome, complexed with L2, is released into 
the cytoplasm [22]. The L2-complexed genome then travels to the nucleus along 
microtubules via dynein-mediated transport [31].  
The infectious cycle of HPV lasts for at least 3 weeks and is closely linked to the 
differentiation program of keratinocytes. Following infection, viral gene expression is 
mostly suppressed, but low levels of the early genes E1 and E2 are expressed which results 
in an increase in viral genome copy number (approximately 50-100 copies per cell) [5,32]. 
Once the keratinocyte leaves the mitotic phase and begins differentiation in the spinous 
layer, the expression of E6 and E7 increases [17]. The viral genome copy number then 
increases to over 1000 per cell followed by the expression of the late genes, resulting in 
the formation of the L1 and L2 capsid proteins [5]. Self-assembly of icosahedral, infectious 
HPV virions occurs which are then released from the upper, cornified epithelium (Figure 
1.3) [17].  
For neoplastic transformation to occur, the HPV genome needs to integrate into the host 
cell genome of the keratinocyte [33]. Integration results in disruption of the E1 and/or E2 
genes as well as the open reading frames (ORFs) adjacent to E2 (affecting E4 and E5 
expression) [33], leading to non-productive infection (i.e. infectious viral progeny is no 
longer produced). The ORFs of E6 and E7 remain undisrupted and therefore these two 
oncoproteins are expressed [3]. The lack of E2 expression also results in higher E6 and E7 
expression since E2 normally regulates their expression [33]. The high levels of E6 and E7, 
in turn, result in uncontrolled cell proliferation and increased DNA damage [33].  
In reality, the time period between HPV infection and the appearance of abnormal cells 
or lesions is highly variable and can range from weeks to months, suggesting that the virus 




Figure 1.3: The HPV infectious cycle is closely linked to keratinocyte differentiation. Viral gene expression 
remains low and tightly controlled in basal keratinocytes. Once the cell  has begun differentiation (enters 
the spinous epithelial layer), viral gene expression is upregulated. Late genes are then expressed and the 
virions are assembled and released from the cornified layer. Figure from [17].  
1.1.3. Immune evasion strategies of HPV 
 
As a pathogen, HPV can be seen as rather successful, since it manages to evade the host 
immune response. As mentioned above, HPVs have a replication cycle closely linked to 
keratinocyte differentiation, which has important consequences in terms of immunity.  
The viral life cycle is non-lytic, as virus particles are shed from fully differentiated cornified 
keratinocytes in the upper epithelium, i.e. cells fated for desquamation [17]. This provides  
little opportunity for antigen retrieval by antigen presenting cells (APCs) as particles are 
shed from areas that are far away from active immune surveillance. Langerhans cells and 
macrophages (as the most likely APCs) are mostly located in the lower epithelial layers  
and they are relatively ineffective in non-inflammatory environments. The lack of virus-
induced cell lysis results in insufficient release of proinflammatory cytokines, therefore 
APCs are neither activated nor induced to migrate to sites of infection [5]. The infected 
keratinocytes are also unlikely to release any cytokines to stimulate an inflammatory 
response, due to the very low levels of viral protein expression in these cells [5]. 
Furthermore, since HPV is exclusively intraepithelial there is no blood-borne phase of 




During viral infection, one of the first lines of host defence is the interferon (IFN) response. 
Type I IFNs (IFN-α and IFN-β) have antiviral and anti-proliferative effects, but HPV has 
mechanisms by which it can minimize the type I IFN response via its E6 and E7 proteins 
[5]. E7 inhibits induction of IFN-α inducible genes as well as activation of the IFN-β 
promoter, and both E6 and E7 directly interact with components of IFN signalling 
cascades, thereby downregulating the interferon response [5,34,35]. In addition to 
affecting the IFN response, HPV E6 also reduces expression of the proinflammatory 
cytokine interleukin (IL)-18 which negatively impacts on IFN-γ production as well as 
priming of T-cells to launch CD8+-mediated responses [36]. High-risk HPV E6 and E7 
further reduce the innate immune response by interfering with the transcription of toll-
like receptor 9 (TLR9) [37] which normally recognises CpG motifs in viral or bacterial 
double-stranded DNA, thereby triggering the release of proinflammatory cytokines 
[37,38]. The E5 protein is also suggested to have a role in immune evasion by inhibiting 
the acidification of endosomes, affecting antigen processing and presentation by APCs 
[34]. By evading the innate immune response, HPV is practically invisible to host defences 
and manages to delay adaptive immune responses for long periods of time which may 
eventually contribute to persistence of the virus.   
Despite these immune evasion strategies, most HPV infections are cleared within 1-2 
years by host cell-mediated immune responses [39]. Unfortunately, approximately 10% 
of infections remain persistent, and women with persistent high-risk HPV infection are at 
risk for developing cervical cancer [5]. The precise reason for persistence is still unknown, 
but it is believed that immunosuppression may play a role here [3,40].  
 
1.1.4. HPV prophylaxis and challenges 
 
Currently, there are no treatments for HPV infection, but highly efficient prophylactic 
vaccines have been developed to prevent infection in unexposed individuals. These are 
non-infectious subunit vaccines which form virus-like particles (VLPs) from the L1 capsid 
protein [10]. To date, three different prophylactic vaccines against HPV have been made 
commercially available. Cervarix, produced by GlaxoSmithKline in insect cells, protects  
against high-risk HPV16 and 18 [41] and Gardasil, produced by Merck in yeast cells, 
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protects against HPV16 and 18 as well as low-risk HPV6 and 11 [42]. The most recently 
developed HPV vaccine is Gardasil 9 (also produced by Merck in yeast) which protects 
against low-risk HPV6 and 11, and against high-risk HPV16, 18, 31, 33, 45, 52 and 58 [43]. 
All three vaccines contain an aluminium salt adjuvant which precipitates the VLPs, leading 
to the slow release of antigen and increased B cell responses , resulting in the production 
of neutralizing IgG antibodies to L1 [44].   
The invention of these prophylactic vaccines has been a huge step towards combating 
HPV infection and ultimately cervical cancer, but some challenges remain. In South Africa, 
the Department of Health has introduced HPV vaccination schemes in public schools, 
where 9-year-old girls receive 2 doses of Cervarix [45]; while this is an important step in 
the right direction, it only targets a small percentage of the population. Any individuals 
who do not fit into this group would need to get the vaccine privately. This can be a major 
issue in developing countries as the vaccines are expensive, and therefore unattainable 
for a large percentage of women in South Africa [46,47]. Another drawback of the vaccines 
is that they are only effective as prophylaxis and there is very little evidence displaying 
that they may offer any benefit to individuals already infected with HPV [48,49]. 
Furthermore, the vaccines only elicit antibody production against specific HPV types, and 
cross-protection against other HPV types is limited [50,51]. HPV45 and 35 are highly 
prevalent in sub-Saharan Africa, where Gardsasil-9 is still unavailable. Taking these 
challenges into account, it is important to develop alternative means of treatment as well 
as therapies. Alternative means that have been investigated thus far include small 
molecule inhibitors of the early stages of HPV infection which can be incorporated into 
inexpensive topical microbicides [52]. Additionally, the naturally-derived sulphated 
polysaccharide carrageenan has been shown to inhibit HPV infection by blocking HPV 
attachment to cells [53]. Carrageenan has been developed into the microbicide 
Carraguard which in addition to inhibiting HPV infection also effectively reduces herpes  
simplex virus 2 (HSV-2) prevalence; however, it was not found to be effective against HIV 
infection [54].  
Enhancing recognition of HPV by the innate immune system represents another 
alternative approach to prevent HPV infection. Identifying innate immune molecules 
which recognise HPV could be beneficial, as these molecules could be incorporated into 
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topical microbicides to prevent infection, especially in immunocompromised individuals. 
Innate immune molecules, such as opsonins which enhance pathogen recognition and 
phagocytosis, generally have a broader range of recognition and therefore could 
potentially be protective against several different HPV types as well as other sexually 
transmitted pathogens.  
 
1.2. Surfactant proteins 
 
Surfactant proteins (SPs) were first identified in pulmonary surfactant, a complex of 
phospholipids and proteins which is responsible for reducing surface tension at the air-
liquid interface of the lung [55]. There are four different surfactant proteins, namely SP-A, 
SP-B, SP-C and SP-D. Together, these SPs make up approximately 7% of lung surfactant, with 
SP-A being the most predominant (5.3%), followed by SP-B (0.7%), SP-D (0.6%) and SP-C 
(0.4%) [56]. SP-B and SP-C are small, hydrophobic proteins which have important roles in 
phospholipid packaging and reducing lung surface tension [56]. SP-A and SP-D however, are 
larger hydrophilic proteins which are strongly involved in the innate immune response, and 
their expression is not restricted to the lung (see section 1.2.3.) [57,58].  
 
1.2.1. Structure of SP-A and SP-D 
 
SP-A and SP-D belong to a family of proteins known as collectins, which are soluble, 
collagenous pattern recognition receptors that tend to be calcium dependent [59]. In 
humans, the genes encoding SP-A and SP-D have been mapped to a cluster on the long 
arm of chromosome 10 (10q 21-24), and SP-A is transcribed by two different genes, 
namely SP-A1 and SP-A2 [60,61]. SP-A and SP-D are mainly produced by type II alveolar 
cells in the alveolus or the non-ciliated bronchial epithelial cells (Clara cells) in the airways 
[57]. The primary structure of the monomeric forms of SP-A and SP-D consists of the 
following: a cysteine-containing amino terminal domain (forms disulphide bonds for 
structural stability), a collagenous domain (important for maintaining the shape and 
structure of the proteins), an alpha-helical neck domain and a carboxy-terminal 
carbohydrate recognition domain (CRD) (Figure 1.4.) [62]. The monomers of SP-A and SP-
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D form trimers (Figure 1.4.), which mostly occurs by the alpha-helical neck domain 
forming a coiled coil with two other monomers, and it is considered that each SP-A trimer 
is formed by one SP-A1 and two SP-A2 monomers [63]. SP-A (30-36kDa monomer) is 
formed by the multimerization of 6 trimers, which forms a bunch-like octadecamer (Figure 
1.4) [57]. SP-D (43kDa monomer) is formed by the multimerization of 4 trimers, which 
forms a cruciform-shaped dodecamer (Figure 1.4) [64].  
The CRD is a common feature of the lectins and it is classified as a region with 14 invariant 
and 18 conserved amino acid residues, which includes 4 cysteine residues which form 
disulphide bonds [65]. The collectin CRDs are trimeric clusters which have a higher affinity 
for clustered oligosaccharides than single monosaccharides : this is thought to be valuable 
in identifying pathogens as the outer surface of pathogens most often comprises of 
clustered oligosaccharides [57]. The binding of CRDs to carbohydrates is often calcium 
dependent, and although structurally similar, SP-A and SP-D have different ligand-binding 
preferences. SP-A preferentially binds to mannose, fucose and lipid ligands, while SP-D 
mostly binds maltose, inositol, glucose and more complex carbohydrates [57,66]. These 
differences in ligand binding might be explained by subtle structural differences in the 
trimeric CRDs: in SP-A, these are flatter and more hydrophobic as compared to the 
hydrophilic CRDs of SP-D which bind to polar ligands [67]. In addition, the Gly-X-Y repeats 
in the collagen domain of SP-A are interrupted, which results in SP-A monomers being 
kinked, whereas in SP-D, the collagenous domain is slightly larger and not kinked which is 
suggested to offer more binding freedom to the distal CRDs [63]. Both SP-A and SP-D have 
very low affinities to galactose and sialic acid  (sugars that often form the terminals of 






Figure 1.4: Structure and assembly of SP-A and SP-D. Monomers of SP-A and SP-D are composed of a 
carbohydrate recognition domain (CRD), neck region, collagenous region and N-terminal region. These form 
trimers which then multimerize to form an octadecamer (SP-A) or dodecamer (SP-D).  
 
1.2.2. Immune functions of SP-A and SP-D 
 
SP-A and SP-D have been described to have numerous innate immune functions, most of 
which have been described in the lung. These innate immune functions include pathogen 
recognition (section 1.2.2.1.) and maintaining lung homeostasis (section 1.2.2.2.). 
Recognition of pathogens by SP-A and SP-D often occurs via their CRDs, and this triggers 
various immune responses (Figure 1.5). These innate responses include opsonising the 
pathogen, which leads to enhanced phagocytosis by immune cells such as alveolar 
macrophages as well as enhanced pathogen killing by neutrophil oxidative responses [57]. 
Additionally, SP-A and SP-D can agglutinate pathogens, thereby causing them to aggregate 
and prevent them from entering host cells. SP-A and SP-D also assist with the clearance 
of apoptotic cells, and they are involved in regulating macrophage function and the 





Figure 1.5: Innate immune functions of SP-A and SP-D. SP-A and SP-D have numerous innate immune 
functions which include interacting with pathogens to either opsonise or aggregate them, clearance of 
apoptotic cells, and regulating macrophage functi on and inflammation.  
 
1.2.2.1. Interaction of SP-A and SP-D with pathogens in the lung 
 
Research on the interaction of SP-A and SP-D with certain pathogens has been most 
extensively done in the context of the lung, but more recent studies have revealed non-
pulmonary functions of SP-A and SP-D (section 1.2.3.).  
In terms of bacterial recognition, SP-A and SP-D are able to recognise pathogen 
associated molecular patterns (PAMPs, usually comprising of clustered 
oligosaccharides) on bacterial surfaces. SP-A and SP-D interact with various bacteria 
including Pseudomonas aeruginosa, Haemophilus influenza and Mycobacterium 
tuberculosis (M.tb), and this often results in bacterial clearance [69–72]. Often, SP-A and 
SP-D perform similar functions, but this is not always the case. For example, SP-A and 
SP-D recognise M.tb with contrasting effects: SP-A enhances the uptake of M.tb by 
monocyte-derived macrophages, whereas SP-D agglutinates M.tb and inhibits bacterial 
uptake by these macrophages [71,72]. Additionally, SP-D increases the fusion of 
macrophage lysosomes with M.tb containing phagosomes, thereby facilitating M.tb 
clearance [73]. These results demonstrate that SP-A may be assisting M.tb access into 
its intracellular niche while SP-D is protecting the host from infection, suggesting that 
SP-D is a more effective innate immune protein in this context.   
Early innate immune responses against viral infections are important to protect the host 
from any significant damage. Influenza A virus (IAV) predominantly infects the 
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respiratory tract, and it has been demonstrated that both SP-A and SP-D are involved in 
controlling IAV infection. SP-A interacts with the IAV glycoproteins haemagglutinin and 
neuraminidase through an N-linked oligosaccharide on the CRD, while SP-D interacts 
with these viral glycoproteins via the CRD in a calcium-dependent manner [74,75].  
These interactions result in aggregation of IAV, which enhances  neutrophil binding to 
the virus and respiratory burst by neutrophils, and this results in clearance of the virus 
from the lung [74]. SP-D levels in the bronchoalveolar lavage fluid (BALF) increase 
following IAV infection, further supporting that SP-D has an important role in controlling 
initial infection [76].  
Respiratory syncytial virus (RSV) is an infectious agent of the respiratory system which 
can give rise to bronchiolitis or pneumonia, especially in infants [77]. The envelope of 
RSV contains two glycoproteins which are vital for the early stages of infection; the F 
protein, involved in viral fusion to host cell membranes, and the G protein, responsible 
for cell attachment [78]. SP-A binds to RSV via the F glycoprotein, and SP-D binds to both 
the F and G glycoproteins in a calcium-dependent manner [77,78]. These interactions  
result in RSV opsonisation and therefore, enhanced phagocytosis of RSV by alveolar 
macrophages. SP-A and SP-D may also act to neutralise the virus, causing a reduction in 
infection [77,78]. Individuals with polymorphisms in the SP-D gene, especially those 
located in the N-terminal of SP-D (Met11Thr), have a higher susceptibility to RSV [79]. 
Additionally, certain alleles of the SP-A2 gene have been linked to more severe RSV in 
infants [80]. These genetic studies emphasize the importance of SP-A and SP-D in 
immunity to RSV.  
Herpes simplex virus type 1 (HSV-1) usually infects the mucosal layer of the mouth, but 
it can also cause respiratory infections, especially in immunocompromised individuals  
[81]. SP-A interacts with HSV-1 via its CRD, and it is suggested that the CRD recognises 
N- and O-linked carbohydrates on the surface of HSV-1 [82]. This results in HSV-1 being 
opsonised by SP-A, and this enhances HSV-1 uptake by alveolar macrophages. To date, 
no studies have been done on SP-D and HSV-1 interactions.   
In addition to recognising a variety of bacteria and viruses, SPs also play a role in immune 
recognition and clearance of various fungi and allergens [63]. Additionally, SP-D has 
been shown to significantly contribute to host defences against the parasitic helminth 
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Nippostrongylus brasiliensis [83]. Overall, SP-A and SP-D have a vital role in protecting 
the lung from infection by pathogens. 
 
1.2.2.2. Role of SP-A and SP-D in maintaining lung homeostasis 
 
By binding to certain receptors on macrophages/immune cells, SP-A and SP-D mediate 
enhanced phagocytosis of various pathogens as described above. Moreover, SP-A and SP-
D enhance apoptotic cell clearance by alveolar macrophages , although SP-A is more 
effective at this [84]. Clearance of apoptotic cells is vital in maintaining homeostasis, as 
ineffective clearance may result in post-apoptotic cytolysis or necrosis followed by tissue 
damage and extended inflammation [85]. SP-A and SP-D can also modulate the 
inflammatory response by binding to macrophage receptors which either enhances or 
suppresses the production of proinflammatory molecules; this depends on the binding 
orientation of the SP to the macrophage receptor. When SP-A or SP-D is bound to a 
pathogen or allergen by the CRD, the collagenous domain binds to CD91-calreticulin 
receptors on the macrophage to induce production of proinflammatory cytokines [86]. 
When there are no foreign particles to interact with, the CRD remains free to interact with 
signal inhibitory regulatory protein alpha (SIRP-α), suppressing proinflammatory mediator 
production [86].  
The significance of SPs in maintaining lung homeostasis has been well demonstrated in 
SP-A or SP-D deficient mice. Not only do these mice have increased susceptibility to 
certain pathogens including H. influenzae, group B streptococcus and IAV, but the 
inflammatory response following infection is also exaggerated [69,87]. Increased 
inflammation and reactive oxygen species production has been linked to emphysema and 
pulmonary fibrosis, and mice lacking either SP-D or both SP-A and SP-D do indeed have an 
emphysemic phenotype [88,89].  
In humans, decreased levels of SP-D have been linked to severe asthma and chronic 
obstructive pulmonary disease; illnesses characterised by increased inflammation [90]. 
Furthermore, SP-A and SP-D levels are reduced in smokers, which could further contribute 
to the development of emphysema and other chronic obstructive pulmonary disorders  in 
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these individuals [91]. These findings emphasise the importance of SP-A and SP-D in 
maintaining lung homeostasis in order to prevent aberrant inflammation and the 
development of certain inflammatory disorders.    
 
1.2.3. SP-A and SP-D in non-pulmonary sites 
 
As mentioned, SP-A and SP-D were first discovered in the lung, but more recently these 
proteins were found to be expressed at other sites throughout the body. These non-
pulmonary sites include the gastrointestinal tract (GIT), urinary tract, female reproductive 
tract, eye, coronary artery and central nervous system as reviewed recently by Ujma et al. 
[58]. Their expression at these diverse sites suggests that they have a more general role 
in innate immunity, rather than just protecting the lung.  
In the GIT, SP-A and SP-D are expressed in the epithelial cells of the small and large 
intestine, and SP-D is also expressed at low levels in the stomach [92,93]. Their functions 
in the GIT appear to be related to controlling infection and inflammation. Experiments on 
porcine GIT have showed that SP-D aggregates and enhances the uptake of various gram-
negative bacteria [94]. SP-A and SP-D also have protective roles in necrotising 
enterocolitis, a disease associated with overexpression of TLR4 in the intestine of pre-
term infants. Pre-treatment of intestinal cell cultures with SP-D show reduced LPS-
induced inflammation [95], while in a rat model of necrotising enterocolitis, oral 
administration of SP-A reduced intestinal pathology, inflammation and mortality [96]. SP-
D in the GIT may also play a role in resolving helminth infections, based on the observation 
that non-pulmonary SP-D is involved in clearing N.brasiliensis infections; however, this is 
currently not well understood [83].  
Urinary tract infections (UTIs) can be caused by external pathogens, and SP-A and SP-D 
may have a protective role in the urinary tract. Both SP-A and SP-D have been detected in 
the kidney and in the epithelium of the ureter and bladder [93,97]. SP-A and SP-D inhibit 
uropathogenic E. coli growth in vitro [97] and SP-D reduces the adherence of bacteria to 
human bladder cells [98].  SP-A and SP-D double knockout mice also display an increased 
susceptibility to UTIs by uropathogenic E. coli [97]. In addition to this, polymorphisms in 
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the SP-A1 or SP-A2 genes have been linked to an increased susceptibility to recurring UTIs, 
further emphasising that SPs are likely to play a protective role in the urinary tract [99].  
In the human female reproductive tract SP-A is located in the myometrium, vaginal 
epithelium and vaginal lavage fluid, and SP-D has been found in the cervix, vagina and 
endometrium [100–102].  In pregnancy, SP-A and SP-D can be detected in the placenta, 
amnion, chorion and the amniotic fluid [102,103]. Numerous studies have shown that SP-
A and SP-D may have a protective role in pregnancy. Both SP-A and SP-D levels are 
elevated in the first trimester decidua (maternal part of the placenta), and the potential 
function of this is to prevent bacterial infection [104]. This is supported by the observation 
that SP-A and SP-D reduce lipopolysaccharide (LPS)-induced inflammation by decidual 
macrophages [105]. Moreover, SP-A-treated amnion explants have decreased cytokine 
expression, suggesting that SP-A reduces amnion inflammation, therefore protecting the 
foetus [106].  
In addition to having protective roles in pregnancy, the expression of SP-A and SP-D in the 
female reproductive tract has been suggested to contribute to innate immune defences 
against sexually transmitted pathogens. An example of this is the observation that SP-D 
inhibits infection of human cervical epithelial cells (HeLa) by Chlamydia trachomatis, and 
murine infections with Chlamydia muridarum enhance SP-D expression in the cervix 
[107,108]. SP-A and SP-D also interact with HIV via oligosaccharides on the HIV envelope 
protein gp120 [109,110]. HIV normally infects CD4 T-cells, and SP-A and SP-D binding to 
HIV inhibits its infectivity of CD4 T-cells, possibly by occluding the CD4 binding site of 
gp120 [109,110]. In contrast, SP-A and SP-D also enhance HIV uptake by dendritic cells, 
which can be seen as unfavourable in terms of host immunity to HIV as the dendritic cells 
transfer the virus to CD4 cells [109,110]. This inhibition of direct infection but 
enhancement of indirect infection indicate that SP-A and SP-D have contrasting effects in 
terms of modulating HIV infection.   
SP-A and SP-D therefore seem to play a role in the innate immune response of the female 
genital tract; however, no research has been conducted on their interaction with HPV and 





1.3. Challenges of studying HPV infection in the laboratory 
 
The ability to produce or isolate infectious HPV is important for the study of HPV binding 
and entry into host cells, as well as studying potential inhibitors of HPV infection. 
Unfortunately, generating native HPV in the laboratory has proven to be a difficult task. 
Since the HPV life cycle is linked to keratinocyte differentiation (section 1.1.2.), generating 
HPV in monolayer cell culture is not viable [14]. The use of organotypic raft cultures and 
mouse xenografts has allowed for native HPV production, but these methods are 
laborious and produce low yields of the virus [111–113]. The production of infectious HPV 
pseudovirions (HPV-PsVs) has been a major breakthrough in the field, as high titres can 
be produced in a relatively simplistic manner. To produce HPV-PsVs, such as HPV16-PsVs, 
the virus packaging cell line HEK293TT (established from HEK293 embryonal human 
kidney cells transformed with sheared adenovirus type 5 and simian virus-40) [114] is 
transfected with an expression plasmid encoding codon-optimised HPV16 L1 and L2 
capsid proteins, as well as a reporter plasmid (Figure 1.6) [115]. Thereafter, the L1 and L2 
proteins spontaneously self-assemble into icosahedral capsids harbouring the reporter 
plasmid, resulting in infectious pseudovirions. The reporter plasmid encoding for example 
firefly luciferase or green fluorescent protein (GFP), replaces the viral genome and can be 
used to quantify successful infection.  
 
 
Figure 1.6: Production of infectious HPV-PsVs. HPV-PsVs are produced by transfecting HEK293TT cells with 
a plasmid encoding type-specific L1 and L2 capsid proteins, as well as a reporter plasmid. This results in the 
spontaneous self-assembly of non-oncogenic, infectious HPV-PsVs, which can be used to study HPV binding, 




HPV-PsVs have successfully been used in cell culture experiments as well as in vivo 
experiments. HPV type 16 pseudovirions, being the most common oncogenic HPV type 
worldwide, are the most widely used in research; however other PsVs types have also 
been generated and used successfully. Important findings regarding HPV binding and 
entry have been elucidated using HPV-PsVs; this includes the finding that HSPGs are the 
initial attachment molecules for HPV, as well as that furin cleavage of the L2 protein is 
necessary for infection [21,26,116–118].  
A major issue with studying HPV using animal models is the highly species -specific modes 
of infection, i.e. native HPV is unable to cause a productive infection in animals [119]. To 
overcome this, various animal models using the appropriate animal papillomavirus (eg: 
bovine papillomavirus in cows) have been used for a variety of applications, such as 
studying viral transmission and cancer development [119]. The more recent discovery of 
a murine papillomavirus which is able to infect laboratory mice strains  has also provided 
a valuable and more accessible tool for studying papillomavirus disease and pathology 
[120,121]. However, the finding that HPV-PsVs successfully recapitulates the initial 
infection phases in murine genital tissue (following gentle abrasion of the epithelium) has 
led to the development of a well-established model of HPV infection in mice [122]. This 
model is advantageous for the study of early entry events, and infection can easily be 
measured using a variety of read-outs, depending on the reporter plasmid used [122]. For 
example, live-imaging systems can be used to detect firefly luciferase expression following 
successful infection [123]. If these systems are unavailable, luciferase assays can be 
performed on genital tract tissue homogenates. Furthermore, the usage of Gaussia 
luciferase, which has a signal peptide for secretion, allows luciferase activity to be 
measured in vaginal lavages which can be performed daily [123]. Therefore, an HPV-PsVs 
murine cervicovaginal challenge model is a useful tool for studying HPV infection in vivo, 








It is hypothesised that SP-A and/or SP-D may protect against HPV infection by binding to the 
virus and functioning as an opsonin, thereby enhancing viral phagocytosis by macrophages 
and preventing infection of keratinocytes.   
 
1.5. Aim  
 
The aim of this study was to determine whether SP-A and/or SP-D play a role in innate 
immune recognition of HPV16-PsVs, thereby preventing infection under both in vitro and in 




• To determine whether HPV16-PsVs bind to purified human SP-A and/or SP-D and 
whether this affects internalisation by RAW264.7 macrophages in vitro. 
• To set up the HPV16-PsVs cervicovaginal challenge model [122], using female C57BL/6 
mice.  
• To observe the effect of surfactant proteins on HPV16-PsVs infection of C57BL/6 mice, 










2. Materials and Methods 
2.1. Materials 
 
Unless otherwise stated, chemicals of analytical/reagent grade were used and generally 
purchased by Merck or Sigma Aldrich. Media, gels and solutions made up in the laboratory 
are detailed in the Appendix.  
 
2.2. Cell culture 
 
The murine leukemic macrophage cell line RAW264.7 (ATCC®), the human epithelial cervical 
adenocarcinoma cell line HeLa (ATCC®) and the virus packaging cell line HEK293TT [114,115] 
were cultured in complete Dulbecco’s Modified Eagle Medium (DMEM) (Appendix). All cells 
were cultured in 75cm2 cell culture flasks (SPL Life Sciences) and incubated in a humidified 
atmosphere containing 5% CO2 at 37°C. Cells were passaged by adding 5mL 0.025% 
trypsin/0.01% Ethylenediaminetetraacetic acid (EDTA) in phosphate buffered saline (PBS) for 
5 minutes at 37°C. 5mL complete medium was then added, and cell suspensions were 
centrifuged in 15mL Falcon tubes (SPL Life Sciences) at 425 x g for 2 minutes to pellet cells. 
Media was removed from the tubes and cell pellets resuspended in 10mL complete medium. 
2mL of the cell suspension was transferred to a 75cm2 cell culture flask containing 10mL 
complete medium. Cells were passaged twice a week.   
 
To count cells for seeding, 10µL cell suspension was added to 90µL trypan blue, which stains 
dead cells. 10µL of this solution was placed on a Neubauer haemocytometer (Marienfeld) 
with a coverslip placed on top. Bright unstained live cells were counted using a microscope 





Cells were seeded at the densities described below for individual experiments. 
 
2.3. Studying HPV infection using HPV16-PsVs 
 
To study HPV infection in vitro and in vivo, non-oncogenic infectious pseudovirions (HPV16-
PsVs) were generated according to the protocol by Christopher Buck [115]. These 
pseudovirions contain a reporter plasmid, which enables quantification of infection once the 
pseudovirus has successfully infected cells. In the majority of the experiments presented 
herein, HPV16-PsVs particles containing the firefly luciferase (FLuc) reporter plasmid pGL3 
(Promega) were used, which results in the transcription and translation of intracellular 
luciferase.  
In certain in vivo experiments, HPV16-PsVs particles containing the Gaussia luciferase (GLuc) 
reporter plasmid pCMV-GLuc 2 (New England Biolabs) were used. Gaussia luciferase is a 
protein derived from the marine copepod Gaussia princeps, which contains an internal signal 
peptide for secretion [124]. Since it is secreted, using HPV particles containing Gaussia 
luciferase can be advantageous in certain experiments (such as time course experiments) as 
luciferase activity can be measured directly from body fluids (such as vaginal lavages) without 
sacrificing the animal (see section 2.9.3.2.).   
Fluorescently labelled HPV16-PsVs particles can also be used to determine viral 
internalisation by flow cytometry and microscopy. In these experiments, Alexa Fluor 488 was 
used to label HPV16-PsVs (see section 2.3.2.). 
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2.3.1. Production of HPV16-PsVs  
 
To produce HPV16-PsVs, HEK293TT cells were seeded in sixteen 10cm dishes (Greiner Bio-
One) in complete DMEM and incubated overnight at 37°C. Per plate, cells were transfected 
with the following plasmids, using the calcium phosphate method: 5µg pXULL [115] (which 
encodes codon-optimised HPV16 L1 and L2) together with either 12µg pGL3 (firefly luciferase) 
or 12µg pCMV-GLuc 2 (Gaussia luciferase). After 48 hours, cells were harvested by 
trypsinization and centrifuged at 425 x g for 2 minutes in a 50mL Falcon tube to pellet cells. 
The cell pellet was resuspended in 1mL 1X PBS and transferred to a 1.5mL siliconized 
Eppendorf tube.  
The cell suspension was centrifuged at 956 x g for 5 minutes. The PBS was removed and the 
cell pellet resuspended in an equal amount of PBS + 9.5mM MgCl2. 1/20 Vol fresh 5% Brij58 
was added to lyse the cells, as well as 1µL Benzonase (Sigma Aldrich) and 1µL Exonuclease V 
(New England Biolabs) for digestion of free (un-encapsidated DNA). The solution was 
incubated at 37°C for 24 hours with occasional mixing to allow for particle maturation. The 
lysate was then chilled on ice and 0.17 Vol PBS + 5M NaCl added, followed by three 
freeze/thawing (-80°C) cycles.  The lysate was then centrifuged at 8000 x g for 10 minutes at 
4°C to pellet cell debris, followed by Alexa Fluor 488 labelling (section 2.3.2.) and HPV16-PsVs 
purification (section 2.3.3.).   
 
2.3.2. HPV16-PsVs labelling with Alexa Fluor 488 
 
To assess viral uptake 1 to 24 hours after infection by flow cytometry or fluorescent 
microscopy, HPV16-PsVs particles were fluorescently labelled with Alexa Fluor 488 
succinimidyl ester (AF488, Invitrogen) before CsCl gradient purification (see 2.3.3.). Prior to 
labelling, the cell lysate’s pH was adjusted with addition of 1/10 Vol 1M NaHCO 3, pH 8.8. 1/10 
Vol AF488 (stock: 10mg/mL in DMSO) was added to the lysate and incubated for 1 hour at 
room temperature (RT) in the dark, rotating. The pH was then corrected by adding 1/25 Vol 




2.3.3. HPV16-PsVs Purification 
 
Caesium chloride ultracentrifugation was used to separate HPV16-PsVs particles from cell 
lysates. This was done by loading the lysate onto a discontinuous CsCl gradient, prepared as 
follows: 4mL light CsCl (1.25 g/mL in 1X HSB, see Appendix) was added to a 13.2mL Ultra-
Clear™ centrifuge tube (Beckman Coulter) followed by 4mL heavy CsCl (1.4 g/mL in 1X HSB) 
which was added gently beneath the light CsCl layer. The interface between the two layers 
was marked on the tube. The cell lysate was then made up to 3.5mL with 1X HSB buffer and 
gently added to the top of the CsCl gradient. Tubes were centrifuged for 16-18 hours at 20 000 
rpm in a Beckman SW40Ti swinging bucket rotor. Following ultracentrifugation, the tubes 
were carefully removed from the rotor and clamped to a ring stand in a biosafety cabinet. The 
viral particles were then extracted from the faint viral band (seen slightly above the CsCl 
interface) using an 18-gauge needle attached to a 5mL syringe inserted below the CsCl 
interface. After gently removing the needle from the tube, the remaining liquid was drained 
into a beaker containing Virkon disinfectant. The sample was then transferred to an Amicon 
Ultra-4 Centrifugal filter unit (Millipore) and centrifuged at 956 x g for 10 minutes, to 
concentrate the pseudovirions. This was followed by washing with 3mL HSB buffer and 
centrifuging at 956 x g for 10 minutes, or until the sample was concentrated to approximately 
100µL. The protein concentration of HPV16-PsVs preparations was then quantified using the 
Pierce™ BCA Protein Assay Kit (Thermo Scientific) (see section 2.7.). HPV16-PsVs preparations  
were stored at -80°C.  
 
2.3.4. Quality checks of HPV16-PsVs preparations 
2.3.4.1. SDS-PAGE and silver staining 
 
SDS-PAGE gels were used to determine the purity of HPV16-PsVs preparations. 3µL of each 
HPV16-PsVs preparation was loaded and electrophoresed as per section 2.5. AF488-labelled 
HPV16-PsVs preparations were visualised using a Biospectrum™ 500 Imaging System (Ultra 
Violet Products, UVP) to detect fluorescent bands at 55kDa, corresponding to AF488 labelled 
L1 protein which is in excess compared to L2 (10-fold higher than L2) [20]. Gels were then 
stained to visualise the L1 and L2 proteins (and possible impurities) of the HPV16-PsVs using 
the Pierce™ Silver Stain Kit (Thermo Scientific), according to the manufacturer’s instructions.  
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Briefly, SDS-PAGE gels were washed in dH2O and then fixed in a 30% ethanol: 10% acetic acid 
solution for 15 minutes. This was followed by further washing with 10% ethanol and dH2O for 
5 minutes each. Gels were then sensitized for staining using a sensitizer working solution 
(provided in kit) for 1 minute, followed by 2 X 1 minute washes with dH2O. Gels were then 
stained for 30 minutes using the silver stain solution, followed by 3 minutes of developing 
using the developing solution (both provided in kit). A predominant L1 band at 55kDa as well 
as a less predominant L2 band at 75kDa were expected in pure preparations.  
 
2.3.4.2. Luciferase infection assay 
 
Luciferase assays were performed to determine the infectivity of HPV16-PsVs preparations. 
Briefly, HeLa cells were seeded in 12-well plates (Greiner Bio-One) at a density of 50 000 cells 
per well and incubated overnight at 37°C. Cells were then infected with HPV16-PsVs in 
duplicate as follows, for 24 hours:  
• HPV16-PsVs only,  
• HPV16-PsVs preincubated for 1 hour at 4°C with the HPV16 neutralising antibody 
H16.V5 (positive control: expected to abolish infection),  
• HPV16-PsVs preincubated for 1 hour at 4°C with the HPV18 neutralising antibody 
H18.J4 (negative control: as HPV18 antibody should not recognise HPV16-PsVs, 
infection should not be effected), 
• HPV16-PsVs treated for 1 hour at 37°C with DNase I endonuclease (Thermo Scientific). 
This will cleave any un-encapsidated plasmid, so that any measured luciferase is due 
to infection only.  
The H16.V5 and H18.J4 neutralising antibodies were provided by Neil D. Christensen, 
Pennsylvania State University College of Medicine, USA. 
For HPV16-PsVs particles containing FLuc, cells were washed with 500µL 1X PBS and lysed by 
adding 100µL 1X Cell Culture Lysis Reagent (Promega) followed by scraping with the back of 
a 100µL-pipette tip. This allowed for any translated luciferase to be released from cells. Cell 
lysates were then transferred to Eppendorf tubes and centrifuged at 10620 x g for 2 minutes  
to pellet cell debris. 20µL of each sample’s supernatant was added to a white 96-well plate 
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(Nunc) and measured using a Fluoroskan™ Ascent Microplate Fluorometer and Luminometer 
(Thermo Scientific) following the Luciferase Assay System (Promega) protocol.  100μL 
Luciferase Assay Substrate (Promega) was added to each well by the luminometer and 
luminescence measured with no lag time over 10 seconds integration time. 
For HPV16-PsVs particles containing GLuc, 5µL cell supernatant was added to a white 96-well 
plate (Nunc) and measured using a Fluoroskan™ Ascent Microplate Fluorometer and 
Luminometer (Thermo Scientific) following the Gaussia Luciferase Assay Kit (New England 
Biolabs) protocol. Per sample, freshly prepared GLuc Assay Solution consisting of 0.5µL BioLux 
GLuc Substrate added to 50µL BioLux Assay Buffer (New England Biolabs) was added per well 
and luminescence measured with 40 seconds lag time over 10 seconds integration time.  
Raw luciferase data (arbitrary units) were normalised to protein concentration (mg/mL) of 
the sample. Protein concentration was determined using the Pierce™ BCA Protein Assay Kit 




Co-immunoprecipitation (Co-IP) experiments were performed to biochemically determine 
whether SP-A and/or SP-D interact with HPV16-PsVs, using some reagents of the Pierce™ Co-
immunoprecipitation kit (Thermo Scientific). This technique involves using an antibody 
recognising a protein of interest/bait protein (either HPV16 L1, SP-A or SP-D) and Protein G 
sepharose beads which bind to the antibody and can be used to “pull down” the protein of 
interest as well as any interacting/prey proteins. These samples can then be analysed by SDS-
PAGE and Western Blotting to detect any prey proteins that have been co-
immunoprecipitated with the bait protein.  
Prior to Co-IP, 5µg purified human SP-A or recombinant human SP-D (both proteins provided 
by Howard Clark and Jens Madsen, University of Southampton, UK) were preincubated with 
0.2µg HPV16-PsVs (or without HPV16-PsVs as a control) in complete DMEM for 1 hour at 4°C. 
Lysis/Wash Buffer (Thermo Scientific) was added to bring each solution’s total volume to 
150µL. 5µL of each of these “input” samples were kept aside for analysis . 2.5µg antibody 
(either CamVir1 against HPV16-L1, anti-SP-A or anti-SP-D) was then added to the appropriate 
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samples and incubated overnight at 4°C, rotating. 25µL Protein G Sepharose beads were 
added to each reaction, and tubes were incubated for 2 hours at 4°C, rotating. Each reaction  
was added to a separate spin column (Thermo Scientific) to simplify sample collection. Flow 
through (FT) samples were collected by centrifugation at 1000 x g for 1 minute. The Protein 
G beads were then washed by adding 200µL Lysis/Wash Buffer and centrifuging at 1000 x g 
for 1 minute. The wash step was repeated twice. A further wash step was performed with 
100µL 1X Conditioning Buffer (Thermo Scientific) followed by centrifugation at 1000 x g for 1 
minute to improve elution. 10µL Elution Buffer (Thermo Scientific) was added to each column 
and centrifuged at 1000 x g for 1 minute. A further 30µL Elution buffer was added to each 
column and incubated for 5 minutes at RT. Columns were centrifuged at 1000 x g for 1 minute 
to collect remaining eluate.  
Input, FT and eluate samples were analysed by SDS-PAGE followed by Western Blotting (see 
section 2.5. and 2.6.). 3µL input and FT and 20µL eluate were loaded per gel. After transfer 
and blocking, CamVir1 primary antibody (Abcam) was added in a 1:2500 dilution in 5% fat free 
milk powder in PBS-Tween and incubated overnight at 4°C while shaking to detect presence 
of the HPV16 L1 protein. The membrane was then incubated with a goat-anti-mouse 
secondary antibody (1:5000 dilution in 5% fat free milk powder in PBS-Tween) and visualised 
as described in section 2.6.  
 
2.5. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
SDS-PAGE is used to separate proteins based on their molecular weights. SDS-PAGE gels 
consisting of a 10% separating and 3% stacking gel were prepared (Appendix). Proteins from 
various experimental samples as indicated were suspended in 5X Lane Marker Sample Buffer 
(Thermo Scientific) containing dithiothreitol (DTT), then heated at 95°C for 5 minutes prior to 
loading the desired amount onto the gel. A Colour Prestained Protein Standard, Broad Range 
protein marker (11–245kDa, New England Biolabs) was used to estimate protein molecular 
weights. Protein samples were electrophoresed in 1X SDS-PAGE running buffer (Appendix) at 




2.6. Western Blot 
 
Western Blotting was performed to detect specific proteins in cell lysates, homogenates or 
protein mixtures. Following SDS-PAGE, proteins were transferred to a 0.2µm nitrocellulose 
membrane (Bio-Rad). The transfer stack was assembled in 1X tris -glycine transfer buffer 
(Appendix) according to Figure 2.1. Protein transfer was performed in 1X tris-glycine transfer 
buffer for 1 hour at 100V in the cold to mitigate heat production. Ponceau S (Appendix) was 
then used to determine successful protein transfer. The membrane was then washed in PBS-
Tween (Appendix) to remove residual Ponceau S. Following this, the membrane was 
incubated in 5% fat free milk powder in PBS-Tween at RT for at least 1 hour shaking, to block 
non-specific protein binding sites. Primary antibody was added in 5% fat free milk powder in 
PBS-Tween and incubated overnight at 4°C, shaking. The membrane was then washed with 
PBS-Tween for 3 X 10 minutes to remove any unbound antibody. Appropriate secondary 
antibodies conjugated to horseradish peroxidase (HRP) were added in 5% fat free milk 
powder in PBS-Tween in a 1:5000 dilution and incubated for 1 hour at RT, shaking. The 
membrane was then washed as abovementioned to remove any unbound secondary 
antibody. Lumi-Glo chemiluminescent substrate (KPL) was used according to the 
manufacturer’s instructions to visualise the proteins of interest. Chemiluminescence was 
visualised using a Biospectrum™ 500 Imaging System (Ultra Violet Products, UVP).  
To remove any primary and secondary antibody bound to the membrane as a prerequisite for 
re-probing the membranes, a harsh stripping solution was used (Appendix). Stripping was 
performed for 5 minutes at RT shaking, and this was repeated 3 times. The membrane was 
then washed with PBS-Tween 3 X 10 minutes and then blocked with 5% fat free milk powder 
in PBS-Tween for 1 hour. The membrane was then re-probed with the appropriate primary 
antibody overnight at 4°C, followed by washing and incubation with the appropriate 





Figure 2.1: Transfer stack assembly for wet transfer Western Blot.  
 
2.7. Protein concentration determination 
  
The protein concentration of various samples was determined using the Pierce™ BCA Protein 
Assay Kit (Thermo Scientific) as per the manufacturer’s instructions. Briefly, 200μL BCA 
working reagent (solution A and B mixed in a 50:1 ratio) was added to 3μL sample in clear 96-
well plates (Greiner Bio-One) and incubated at 37ºC for 30 minutes. Absorbance was 
measured at 562nm using an iMark™ Microplate Reader (Bio-Rad) and Microplate Manager 
Software (version 6, Bio-Rad). A standard curve of known concentrations (between 0 and 
2mg) of bovine serum albumin (BSA) was used to calculate the protein concentration of 
various samples.  
 
2.8. Flow Cytometry 
 
Various flow cytometry experiments were conducted to quantify viral internalisation by 
RAW264.7 macrophages. These involved using AF488-labelled HPV16-PsVs, as AF488 emits 
fluorescence when excited by a 488nm laser, allowing for detection of any internalised virus. 
All conditions tested were performed in duplicate on RAW264.7 cells, with three independent 






2.8.1. Viral internalisation in the presence of SP-A or SP-D 
 
RAW264.7 cells were seeded in 6-well plates (Greiner Bio-One) at a density of 5x105 cells per 
well and incubated overnight at 37°C. Before addition to cells, per well 0.5µg AF488-labelled 
HPV16-PsVs were incubated with 5µg purified SP-A, recombinant SP-D or BSA for 1 hour at 
4°C. Cells were infected with these preincubated AF488-labelled HPV particles for 1 hour at 
37°C. Following infection, medium was removed from each well and cells were washed 3 
times with 1X PBS. Cells were harvested by incubating cells with 200µL trypsin/EDTA for 5 
minutes at 37°C, which also removed any cell-surface bound virus to allow for quantification 
of internalisation only [125,126]. 400µL complete DMEM was then added to each well and 
cells were gently scraped using the back of a 100µL pipette tip to assist with cell harvesting. 
Cell suspensions were transferred to 1.5mL Eppendorf tubes and centrifuged at 700 x g for 2 
minutes at 4°C. The supernatant was removed and each cell pellet resuspended in 500µL FACS 
wash (Appendix). Cells were centrifuged at 700 x g for 2 minutes at 4°C and the supernatant 
removed. Cells were fixed by resuspending the cell pellets in 300µL FACS fix (Appendix) and 
samples were then transferred to 5mL polystyrene round-bottom tubes (Falcon) and kept at 
4°C until analysis. Samples were prepared in dark conditions to prevent fading of the AF488 
fluorescence.  
Data were acquired using a BD FACSCalibur™ together with the BD CellQuest™ Pro software 
(Version 5.2.1, BD Biosciences). Acquisition parameters were determined using uninfected 
cells (negative control). The cell population was gated using the dot plot showing forward 
scatter (FSC) versus side scatter (SSC) of the negative control (Supplementary Figure 1). Gating 
was done to exclude any contaminants and cell debris. Dot plots of fluorescence in the FL1 
channel (AF488 positive cells) versus SSC were generated in BD CellQuest™ Pro and quadrant 
statistics determined.  
Statistical analysis was performed on the percentage of AF488 positive cells (cells observed in 
the lower right quadrant) for the gated cell population. Data was assessed for normality using 
the Shapiro-Wilk test in STATA. One-way analysis of variance (ANOVA) and Tukey post-hoc 
tests were performed using Graph Pad Prism 5 (Graph Pad Software), to determine the 




2.8.2. SP-A and AF488-HPV16-PsVs interaction 
 
To characterise SP-A-mediated AF488-HPV16-PsVs internalisation by RAW264.7 cells, 
experiments using mannose, calcium and EDTA were performed. RAW264.7 cells were 
seeded in 6-well plates at a density of 5x105 cells and incubated overnight at 37°C. 5µg SP-A 
was preincubated with: 20mM, 100mM and 200mM mannose in PBS; 2mM and 5mM CaCl2; 
and 2mM and 5mM CaCl2 with 10mM EDTA. This preincubation was done for 1 hour at 37°C. 
AF488-HPV16-PsVs was added to each tube and incubated for 1 hour at 4°C. Cells were 
infected, harvested and analysed as described in 2.8.1.  
 
2.9. In vivo infection of female C57BL/6 mice with HPV16-PsVs 
 
All in vivo experiments were performed on female, 6-10-week-old C57BL/6 mice (University 
of Cape Town, UCT). Mice were housed in the UCT Research Animal Facility (RAF) Biosafety 
Level 2 laboratory in individually ventilated cages, with 4-6 mice per cage. Food pellets and 
water were always available, and cages contained sawdust bedding and shredded tissue 
paper as well as a red house for enrichment. Animal welfare was monitored daily, which 
included weighing the mice to detect any weight loss. While any procedures were performed, 
mice were kept warm using an infrared lamp, and constantly monitored. All experiments were 
approved by the Faculty of Health Sciences Research Animal Committee at UCT (ethics 
number: 016/008).    
In vivo experiments were based on the protocol by Roberts et al. [122] and performed with 
assistance from Dr Georgia Schäfer or Alisha Chetty. 4 days prior to infection, mice were 
injected subcutaneously (s.c.) with 100µL 2mg/20g Depo-Provera (Pfizer) to equilibrate 
hormone levels as well as to help facilitate infection by thinning the vaginal epithelium (Figure 
2.2.) [122]. 6 hours before infection, mice were lightly anaesthetised by intra-peritoneal (IP) 
injection with 125µL 1.5mg/20g ketamine + 0.2mg/20g xylazine. Following this, vaginal 
lavages were performed with 50µL sterile PBS. 25µL 4% nonoxynol-9 (N-9, US Pharmacopeia) 
in 3% carboxymethylcellulose (CMC) was then added to the genital tract, as N-9 is known to 
chemically disrupt the vaginal and cervical epithelium, facilitating HPV infection [127]. After 
6 hours, mice were anaesthetized as above and infected intravaginally (i.vag.) with 3µg 
32 
 
HPV16-PsVs (unless otherwise indicated) in 3% CMC. Control mice (uninfected mice) were 
also anaesthetized and 3% CMC was added i.vag. For time course experiments, vaginal lavages 
were performed daily with 50µL sterile PBS and stored at -80°C until analysis. Depending on 
the read-out as indicated, 1 day or 3 days post infection (p.i.), mice were euthanized using 
halothane and death was confirmed by cervical dislocation. Following confirmation of death, 
vaginal lavages were performed with 50µL sterile PBS. The peritoneal cavity was opened using 
dissecting scissors, and the genital tract exposed by moving the cecum and colon. The bladder 
was then cut away from the vagina, and the genital tract excised. Fat and connective tissue 
were then removed from the genital tract tissue (Figure 2.3.). The fallopian tubes and ovaries 
were removed, and the remaining genital tract (uterus, cervix and vagina) was process ed as 




Figure 2.2: Mouse model for HPV16-PsVs infection using C57BL/6 mice, adapted from Roberts et al. [122].  
 
To determine the effect of SP-A on HPV16 infection in vivo, 3µg HPV16-PsVs was pre-
incubated with 1 and 10-fold excess (w/w) of SP-A in 1X PBS (total volume of 25µL per mouse) 






Figure 2.3 Female C57BL/6 mouse genital tract. Red line indicates where tissue was cut, and only tissue below 
this l ine was used in experiments.  
 
2.9.1. Processing of samples from in vivo HPV16-PsVs infection of female C57BL/6 
mice 
2.9.1.1. Quantification of infection using firefly luciferase assays  
 
To measure luciferase activity in vaginal lavages, 4µL 5X Cell Culture Lysis Reagent (Promega) 
was added to 16µL lavage in order to lyse cells shed in the lavage and release any translated 
luciferase enzyme. This solution was briefly mixed and allowed to incubate for 30 minutes at 
RT. Following this, samples were centrifuged at 10620 x g for 10 minutes at 4°C. Supernatants 
were then removed and added to a new Eppendorf tube. 20µL of each sample was added to 
a white 96-well plate (Nunc) and measured using a Fluoroskan™ Ascent Microplate 
Fluorometer and Luminometer (Thermo Scientific) following the Luciferase Assay System 
(Promega) protocol.  100μL Luciferase Assay Substrate (Promega) was added to each well by 
the luminometer and luminescence measured with no lag time over 10 seconds integration 
time. 
To measure luciferase activity in genital tract tissue, tissue was first snap frozen in liquid 
nitrogen and stored at -80°C until needed. Tissue was homogenised on ice in 500µL 1X Cell 
Culture Lysis Reagent (Promega) using a Polytron™ PT1200E handheld homogenizer 
(Kinematica) for 3 minutes or until the tissue was sufficiently homogenised. Homogenates 
were then centrifuged at 10620 x g for 10 minutes at 4°C to pellet tissue debris. The 
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supernatants were then removed and placed into new Eppendorf tubes. Samples were then 
added to a white 96-well plate and measured as described for the vaginal lavages.  
Raw luciferase data (arbitrary units) were normalised to protein concentration (mg/mL) of 
the sample. Protein concentration was determined using the Pierce™ BCA Protein Assay Kit 
(Thermo Scientific) (section 2.7.). 
 
2.9.1.2. Quantification of infection using Gaussia luciferase assays  
 
To measure luciferase activity in the vaginal lavages of mice infected with GLuc HPV16-PsVs, 
5µL lavage was added directly to a white 96-well plate and measured using a Fluoroskan™ 
Ascent Microplate Fluorometer and Luminometer (Thermo Scientific) following the Gaussia 
Luciferase Assay Kit (New England Biolabs) protocol. Per sample, freshly prepared GLuc Assay 
Solution consisting of 0.5µL BioLux GLuc Substrate added to 50µL BioLux Assay Buffer (New 
England Biolabs) was added per well and luminescence measured with 40 seconds lag time 
over 10 seconds integration time.  
To measure luciferase activity in the genital tract, tissue was first homogenised and the 
supernatant removed from the tissue debris as described in section 2.9.1.1. 10µL of the 
supernatant was added to a white 96-well plate and measured as described for the vaginal 
lavages above.  
Raw luciferase data were normalised as described above. 
 
2.9.2. Protein expression analysis  
 
Western blotting was used to detect expression of SP-A protein in tissue samples from naïve 
as well as HPV16-PsVs challenged mice at the indicated time points. Briefly, 20µg vaginal 
lavage or genital tract homogenate was subjected to SDS-PAGE as described in section 2.5. 
Proteins were then transferred to a 0.2µm nitrocellulose membrane, stained with Ponceau S 
and blocked as described in section 2.6. Rabbit-anti-mouse SP-A primary antibody was added 
in 5% fat free milk powder in PBS-Tween at a 1:5000 dilution and incubated overnight at 4°C, 
shaking. The membrane was then washed 3 X 10 minutes in PBS-Tween. Mouse-anti-rabbit 
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secondary antibody (Jackson Laboratories) was added in 5% fat free milk powder in PBS-
Tween in a 1:5000 dilution and incubated for 1 hour at RT, shaking. The membrane was then 
washed and visualised as described in section 2.6. 
 
2.9.3. Gene expression analysis 
2.9.3.1. RNA extraction  
 
RNA was extracted from uninfected murine tissue (lung and genital tract) and HPV16-PsVs 
challenged murine tissue (genital tract) using the TRIzol™ Reagent protocol (Invitrogen). 
Briefly, 50mg tissue was homogenized in 500µL TRIzol (Life Technologies), using a Polytron™ 
PT1200E handheld homogenizer (Kinematica). Following this, an additional 500µL TRIzol was 
added to the homogenate and incubated for 5 minutes at RT to allow for complete 
dissociation of nucleoprotein complexes. 200µL chloroform was then added to the 
homogenate and the tube inverted 5 times, followed by a 3 minute incubation at RT. Samples 
were then centrifuged at 12 000 x g for 15 minutes at 4°C to allow for phase separation (lower 
red phenol-chloroform phase, middle white interphase and upper clear aqueous phase). The 
upper aqueous phase (containing the RNA) was carefully transferred to a new tube and 500µL 
isopropanol was added to it. Tubes were then gently inverted and left to incubate at RT for 
10 minutes, followed by centrifugation at 12 000 x g for 10 minutes at 4°C. The supernatant 
was then removed, and the RNA pellet was resuspended in 1mL 75% ethanol. This was then 
briefly vortexed and centrifuged at 7 500 x g for 5 minutes at 4°C. The supernatant was 
removed and the pellet allowed to air dry for 10 minutes. RNA pellets were then resuspended 
in 30µL nuclease free water (Thermo Scientific) and the concentration measured using a 
NanoDrop 2000 Spectrophotometer (Thermo Scientific). RNA purity was determined by 







2.9.3.2. DNase I treatment 
 
To remove any genomic DNA from RNA samples, samples were treated with DNase I 
endonuclease (Thermo Scientific). Briefly, 1µL 10X Reaction Buffer (containing Mg 2+) and 1U 
DNase was added to 1µg extracted RNA. The volume was then made up to 10µL with nuclease 
free water, and samples were incubated for 30 minutes at 37°C. Samples were then cleaned 
by ethanol precipitation (section 2.9.3.3.).  
 
2.9.3.3. Ethanol precipitation 
 
Ethanol precipitation was performed to remove any DNase I from RNA samples. Briefly, DNase 
I treated RNA samples were made up to 400µL with nuclease free water, and 50µL 3M sodium 
acetate as well as 1.5mL 96% ethanol was added. Samples were vortexed for 10 seconds and 
stored at -80°C overnight. The following day, samples were centrifuged at 13 000 x g for 20 
minutes at 4°C. The supernatant was then removed and 200µL cold 96% ethanol was added 
to each sample. Following centrifugation at 13 000 x g for 5 minutes, the ethanol was removed 
and the pellet left to air dry for 20 minutes. The pellet was then resuspended in 10µL nuclease 
free water and RNA concentration and purity measured as described in section 2.9.3.1.  
 
2.9.3.4. Reverse transcription of RNA  
 
RNA was reverse transcribed using the High Capacity cDNA reverse transcription kit (Applied 
Biosystems), according to the manufacturer’s instructions. Briefly, a 2X Reverse Transcription 
master mix was prepared containing the following: 0.8µL 100mM deoxynucleotide 
triphosphate (dNTP) mix, 2µL 10x RT Random Primers, 2µL 10X RT Buffer, 1µL MultiScribe™ 
Reverse Transcriptase (50U/µL), 1µL RNase Inhibitor and 3.2µL nuclease free water. For each 
reaction, 1µg RNA was made up to a total volume of 10µL with nuclease free water in PCR 
tubes. 10µL of the 2X Reverse Transcription master mix was then added to each RNA sample, 
and mixed by gentle pipetting. PCR tubes were then sealed and briefly centrifuged prior to 
reverse transcription under the following conditions using the Gene Amp® PCR system 2700 
(Applied Biosystems): 25°C for 10 minutes annealing, 37°C for 120 minutes elongation and 
37 
 
85°C for 5 minutes denaturing. The generated cDNA samples were then stored at -20°C until  
needed.  
 
2.9.3.5. Polymerase chain reaction (PCR) 
 
To determine the expression of selected genes, PCR was performed on the cDNA samples 
derived from the reverse transcription step (2.9.3.4.) using gene-specific primers (Table 2.1.). 
The PCR reaction mix containing 2.5µL 10X DreamTaq Buffer (Fermentas), 1µL 10µM forward 
primer, 1µL 10µM reverse primer, 1µL 10µM dNTP mix, 0.2µL DreamTaq (5U/µL) and 17.5µL 
nuclease free water was added to 1µL cDNA (or water as negative control) and mixed by 
gentle pipetting. PCR tubes were then sealed and briefly centrifuged prior to PCR. The 
parameters in Table 2.2. were used for thermal cycling on the Gene Amp® PCR system 2700 
(Applied Biosystems). Following this, PCR products were electrophores ed as described in 
section 2.9.3.6.  
 
Table 2.1: Primers used for PCR analysis of cDNA 
Gene Forward primer 5’-3’ Length 
(bp) 





SP-A ACCTGGATGAGGAGCTTAGACTGC 25 TGCTTGCGATGGCCTCGTTCT 21 225 
Gapdh CCAATGTGTCCGTCGTGGATCT 22 GTTGAAGTCGCAGGAGACAACC 22 148 
pGL3  CGGGCGCGGTCGGTAAAGT 19 AACAACGGCGGCGGGAAGT 19 380 
 
Table 2.2: PCR thermal cycling conditions 
Step Temperature (°C) Time Cycles 
Initial denaturation 95 3 minutes 1 
Denaturation 95 30 seconds  
35 Annealing 60 30 seconds 
Extension 72 30 seconds 




2.9.3.6. Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to visualise PCR products. 5µL PCR product was mixed 
with 1µL 6X DNA loading dye (Appendix) and loaded onto a 100mL 2% agarose gel containing 
6µL Sybr Safe (Invitrogen). 5µL O’GeneRuler 100bp DNA ladder (Thermo Scientific) was also 
loaded onto the gel in order to determine product sizes. Products were electrophoresed for 
1 hour at 100V in 1X TAE buffer (Appendix). Gels were visualised using a G:Box Imaging System 




To visualise macrophages and viral particles by immunohistochemistry (IHC), the genital tract 
tissue dissected from uninfected and AF488-HPV16-PsVs (preincubated with BSA or SP-A) 
infected mice was prepared for cryosectioning following standard procedures. Briefly, the 
genital tract tissue was first placed in 4% paraformaldehyde for 1 hour to fix the tissue which 
was then washed 3 X 10 minutes in 1X PBS. Following washing steps, the tissue was suspended 
in a 30% sucrose solution overnight at 4°C in order to displace any water from cellular spaces 
and therefore “cryoprotect” the tissue. Excess sucrose solution was then removed from the 
tissue by gently blotting with paper towel, and tissue was embedded in Optimal Cutting 
Temperature (OCT, Sakura Finetec USA) compound in a plastic mould (Sakura Finetec USA) 
and frozen over dry ice. Tissue blocks were stored at -80°C until cryosectioning. Tissue 
sections of 20µm were cut using a Leica CM1850 cryostat. These sections were placed on 
microscope slides coated with 3-Aminopropyltriethoxysilane (APES), which allowed the tissue 
to adhere to the slides. Samples were then air dried overnight, protected from light. Slides 
were stored at 4°C for up to a week or at -80°C long-term, protected from light.  
Before any IHC staining, samples were removed from storage and left at RT for 30 minutes. 
Sections were then immersed in cold methanol and incubated for 10 minutes at -20°C to fix 
and permeabilise sections. Sections were then washed 3 times in 1X PBS, 10 minutes each. 
Following washing, sections were incubated in IHC blocking solution (Appendix) for 1 hour at 
RT to reduce non-specific staining. To stain for macrophages, sections were incubated with a 
specific antibody against murine macrophage surface protein F4/80 (rat-anti-mouse F4/80, 
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Thermo Scientific) at a dilution of 1:1000 in IHC blocking solution overnight at 4°C in a sealed 
humidified chamber. Non-specific background signal was controlled for by using a rat IgG2B 
isotype control (Invitrogen) at a dilution of 1:1000 in blocking solution overnight at 4°C in a 
sealed humidified chamber. Sections were then washed 3 times in 1X PBS, 10 minutes each. 
Goat-anti-rat AF555 secondary antibody (Invitrogen) was added to the sections at a 1:500 
dilution in blocking solution for 90 minutes at RT. This was followed by washing as described 
above. Sections were then incubated in Hoechst Nuclear Stain (0.5µg/mL in 1X PBS) for 10 
minutes at RT, protected from light. After incubation, slides were washed in 1X PBS for 10 
minutes. Sections were then mounted with 20mm x 20mm coverslips using Mowiol  (Sigma 
Aldrich), which contained n-propylgallate for its anti-fade properties. Slides were stored at 
4°C protected from light until viewing.   
Tissue sections were viewed with assistance from Associate Professor Dirk Lang and Mrs . 
Susan Cooper using a Zeiss LSM880 Airyscan confocal microscope together with Zen 2.3 SP1 
software (Zeiss). Ten areas in the epithelium were randomly selected for each condition, using 
the Hoechst channel only to eliminate bias. Z-stacks were then taken with the Hoechst, AF488 
and AF555 channels selected. Z-stack dimensions were then normalised to 18 optical sections 
per image stack, and maximum intensity projections were done. The area occupied by 
macrophages (positive for F4/80) in the epithelium was determined by outlining the 
epithelium in each maximum intensity projection and determining the area of the AF555 stain 
in these selected regions (see Supplementary Figure 2 for an example). The lower and upper 
thresholds were set at 18 and 256 greyscale levels, respectively, for each maximum intensity 
projection. This was done to remove background signal so that the measured signal for AF555 








3.1. Determining the biochemical and functional relevance of SP-A and SP-D for 
HPV16-PsVs infection in vitro  
 
In vitro experiments were performed to determine whether SP-A and/or SP-D play a role in 
immune recognition of HPV16-PsVs. Initially, Co-IP experiments were done to determine 
whether SP-A and/or SP-D interact with HPV16-PsVs particles. Following this, flow cytometry 
was used to determine whether any potential interaction between HPV16-PsVs and SP-A or 
SP-D had a functional consequence on viral internalisation by RAW264.7 macrophages.  
 
3.1.1. Quality control to test the purity and infectivity of HPV16-PsVs preparations 
 
Following the production of HPV16-PsVs, particle purity and functionality was routinely 
tested. SDS-PAGE followed by silver staining was used to assess purity of the HPV16-PsVs 
preparations (Figure 3.1.A, left panel). In pure preparations, only 2 bands, i.e. a thick L1 band 
(55kDa) and thin L2 band (75kDa) were observed as expected. In experiments where AF488 
labelled PsVs preparations were generated, the SDS gels were illuminated with a 488nm light 
source in order to visualise the successfully labelled fluorescent bands prior to silver staining 
(Figure 3.1.A, right panel).  
The infectivity of HPV16-PsVs preparations was assessed by infecting HeLa cells with viral 
particles that had undergone certain pre-incubations or treatments (Figure 3.1.B.). Pre-
incubation of HPV16-PsVs with the appropriate, type-specific neutralising antibody H16.V5 
completely abolished infection as expected (Figure 3.1.B.). Conversely, pre-incubation with 
the HPV18 neutralising antibody H18.J4 (negative control) had no effect on infection, as this 
antibody fails to bind and neutralise HPV16 (Figure 3.1.B.). Treatment with DNase I 
endonuclease was performed to assess whether any un-encapsidated plasmid gave rise to 
the measured luciferase activity. In pure preparations, DNAse treatment showed a similar 
HPV16-PsVs infectivity compared to untreated control (Figure 3.1.B).  




Figure 3.1: Quality control tests to assess purity and infectivity of HPV16-PsVs preparations. A) SDS-PAGE 
gel showing 2 representative HPV16-PsVs preparations (either unlabelled or labelled with AF488). A thick 
band corresponding to the L1 protein (55kDa) as well as a thin L2 band (75kDa) were seen in pure 
preparations. Fluorescent bands were confirmed in AF488 labelled preparations. B) HeLa cells were infected 
with HPV16-PsVs under various conditions for 24 hours before luminescence was measured. Relative 
luciferase activity (R.L.U) represents luminescence (arbitrary units) normalised to protein concentration 
(mg/mL), and values are presented as x-fold change relative to HPV16-PsVs only, which was set as 1. Bars 







3.1.2. SP-A binds to and enhances HPV16-PsVs uptake by RAW264.7 macrophages 
 
In order to determine whether SP-A and/or SP-D bind to the viral particles, co-
immunoprecipitation (Co-IP) was applied. The principle behind Co-IP is that if one 
immunoprecipitates a protein (using the appropriate IP antibody and protein G Sepharose 
beads), any interacting proteins will be co-immunoprecipitated. Any unbound proteins can be 
detected in the flow through (FT) fraction, whereas co-immunoprecipitated proteins are 
detected in the eluate (see section 2.4.). The pull-down was performed with antibodies 
against SP-A or SP-D (or HPV16 L1 as a control, as it will recognise HPV16-PsVs) as indicated 
in Figure 3.2. A-C. Binding of HPV16-PsVs was visualised by Western Blotting using the HPV16 
L1 primary antibody CamVir. The control experiment in Figure 3.2.A. demonstrates that the 
SP-A IP (pull-down) antibody did not cross-react with HPV16-PsVs, while the CamVir IP 
antibody did not recognise SP-A. In the right panel of Figure 3.2.A. (SP-A as an input), bands 
were seen in the FT and eluate lanes, but these were due to the CamVir detection antibody 
recognising a portion of the CamVir IP antibody. This was also found in control experiments  
with SP-D (not shown). The left panel of Figure 3.2.B. shows that the CamVir IP antibody 
recognises HPV16-PsVs as expected (as it is eluted), and some HPV16-PsVs was also detected 
in the FT, most likely due to oversaturation of the IP antibody. Importantly, SP-A binding to 
HPV16-PsVs can be seen in the right panel of Figure 3.2.B, which shows that HPV16-PsVs could 
be detected in the eluate when immunoprecipitated with the SP-A antibody. Figure 3.2.C. 
shows that HPV16-PsVs also bind to SP-D; however, this interaction is much weaker, and only 
a faint HPV16-PsVs was detected in the eluate with the majority still unbound in the FT. 
In order to determine any functional impact of SP-A or SP-D binding for HPV16-PsVs 
recognition and internalisation by RAW264.7 macrophages, flow cytometry experiments  
using AF488-HPV16-PsVs were performed. Figure 3.2.D. shows the fluorescence measured in 
RAW264.7 cells following 1 hour incubation of these cells with AF488-HPV16-PsVs which were 
pre-incubated with SP-A, SP-D or BSA as a control. It was observed that when the viral 
particles were pre-incubated with a 10-fold (w/w) excess of SP-A (as determined in pilot 
experiments, see Supplementary Figure 3), viral internalisation by RAW264.7 macrophages 
was significantly enhanced (p<0.001). Pre-incubation of AF488-HPV16-PsVs with a 10-fold 
43 
 
(w/w) excess of SP-D, however, had no effect on viral internalisation, which was also observed 
with the BSA control.  
Downstream luciferase activity was also determined 48 hours post-infection as a measure of 
successful infection, i.e. the transcription of the firefly luciferase plasmid encapsidated in the 
viral particle representing the pseudogenome entry into the nucleus. We noted that the 
infectivity of RAW264.7 macrophages compared to HeLa cells was extremely low 
(approximately 15 000-fold less, Figure 3.2.E.). However, when HPV16-PsVs were pre-
incubated with a 10-fold (w/w) excess of SP-A, luciferase activity measured in RAW264.7 cells 
increased by approximately 3-fold, but had no effect on HeLa cell infection (Figure 3.2.E).  
From these results, it was decided to concentrate our experiments on viral uptake (rather 
than infection) using RAW264.7 macrophages and SP-A only, to test our hypothesis that 
macrophages prevent epithelial HPV infection by effectively engulfing the HPV which is 









Figure 3.2: SP-A binds to and enhances HPV16-PsVs uptake by RAW264.7 macrophages. A-C) Co-
immunoprecipitation experiments displaying the input, flow through (FT) and eluate samples of (A) HPV16-
PsVs and SP-A alone (controls), (B) HPV16-PsVs and SP-A together and (C) HPV16-PsVs and SP-D together . 
Western Blots were performed using the anti-HPV16 L1 antibody (CamVir) to detect the presence of HPV16-
L1. D) RAW264.7 cells were incubated with AF488 labelled HPV16-PsVs (pre-incubated with purified 
proteins where indicated) for 1 hour at 37°C. Cells were lifted with trypsin-EDTA to remove surface-bound 
virions and subjected to flow cytometry to quantify viral internalisation. Experiments were performed in 
triplicate, quantified by quadrant analysis of the dot blot of three independent experiments (Supplementary 
Figure 4) and presented as x-fold increase relative to the mean fluorescence intensity of cells infected with 
untreated HPV16-PsVs which was set as 1. Significances were calculated by means of one-way ANOVA and 
Tukey post-hoc tests. *** indicates statistical significance between uptake of HPV16-PsVs in the presence 
of SP-A as compared to the other tested conditions (*** = p<0.001). E) RAW264.7 and HeLa cells were 
incubated with HPV16-PsVs for 48 hours. Where indicated, the viral particles were pre-incubated with 
purified SP-A protein before incubation with the cells . Luciferase activities in the cell  lysates as a measure 
for infection is presented as Relative luciferase activity relative to RAW264.7 cells incubated with untreated 








3.1.3. SP-A-mediated HPV16-PsVs uptake by RAW264.7 macrophages is calcium 
dependent and CRD independent 
 
To elucidate the mechanisms by which SP-A mediates increased HPV16-PsVs uptake by 
RAW264.7 macrophages, internalisation experiments in the presence of calcium or mannose 
were conducted.  
Firstly, calcium chloride was used to determine if SP-A-mediated increase in HPV16-PsVs 
uptake was calcium-dependent as SP-A, being a C-type lectin, typically requires calcium to 
perform certain functions. EDTA was used to chelate Ca2+ ions and further determine if 
calcium was necessary for this interaction. Figure 3.3. A-C show control experiments  
displaying viral uptake in the presence of no HPV16-PsVs (Figure 3.3.A.), HPV16-PsVs only 
(Figure 3.3.B.) and HPV16-PsVs with SP-A (Figure 3.3.C.). Figure 3.3. D-E and I show that 
addition of 2mM and 5mM calcium chloride significantly increased viral internalisation in the 
presence of SP-A, with 5mM calcium chloride having the greater effect (p<0.001). Addition of 
10mM EDTA successfully abolished this effect, as shown in Figure 3.3. F-H and I, thereby 
confirming that the SP-A-mediated increase in viral uptake by RAW264.7 macrophages was 
calcium dependent. 
Secondly, in order to determine if SP-A interacts with HPV16-PsVs via its CRD, uptake 
experiments were conducted in the presence or absence of mannose, a competitive inhibitor 
of the CRD [68,128]. The representative dot plots obtained following flow cytometry (Figure 
3.4. A-F) as well as the bar graph in Figure 3.4.G. show that increasing concentrations of 





Figure 3.3: SP-A-mediated HPV16-PsVs uptake by RAW264.7 macrophages is calcium-dependent. AF488-
HPV16-PsVs were incubated in the presence of 10-fold (w/w) excess SP-A with or without 2mM or 5mM 
calcium chloride in the presence or absence of 10mM EDTA as indicated. Representative figures (A-H) show 
dot plots of fluorescence in the FL1 channel plotted against side scatter (SSC) for  (A) No HPV16-PsVs, (B) 
HPV16-PsVs only (C) SP-A, (D) SP-A + 2mM CaCl2, (E) SP-A + 5mM CaCl2, (F) SP-A + 10mM EDTA, (G) SP-A + 
2mM CaCl2 + 10mM EDTA and (H) SP-A + 5mM CaCl2 + 10mM EDTA. Figure I shows a summary of the 
fluorescence measured in the lower right quadrant (AF488 positive) normalised by setting SP-A as 1 for the 
conditions displayed in Figures C-H. Quantification of three independent experiments performed in 
duplicate are shown. Statistical significance was determined using one-way ANOVA and Tukey post-hoc 






Figure 3.4: The SP-A-mediated increase in HPV16-PsVs uptake by RAW264.7 macrophages is not 
dependent on the CRD. AF488-HPV16-PsVs were incubated in the presence of a 10-fold (w/w) excess of SP-
A and various concentrations of mannose. Representative figures (A-F) show dot plots of fluorescence in 
the FL1 channel plotted against side scatter (SSC) for (A) No HPV16-PsVs, (B) HPV16-PsVs only, (C) SP-A, (D) 
SP-A + 20mM mannose, (E) SP-A + 100mM mannose and (F) SP-A + 200mM mannose. Figure G shows a 
summary of the fluorescence measured in the lower right quadrant (AF488 positive) normalised by setting 
SP-A only as 1 for the conditions displayed in Figures C-F. Quantification of three independent experiments 













3.2. Set up of a genital HPV16-PsVs infection model at UCT using C57BL/6 mice 
 
While the in vitro findings described above suggest a role of SP-A in enhancing immune 
recognition of incoming HPV16-PsVs, the natural HPV infection environment in the genital 
tract is very complex as several diverse cell types are potentially involved in immune 
responses upon challenge with oncogenic HPV, including local epithelial cells and the 
recruitment of inflammatory cells. To this end, the cervicovaginal challenge model described 
by Roberts et al. [122], which particularly reflects early events in HPV infection, was set up at 
the UCT RAF as part of this MSc project.  
 
3.2.1. Welfare monitoring of C57BL/6 mice for the duration of HPV16-PsVs 
challenge  
 
An important aspect of animal work is to ensure that the animals do not undergo distress, 
which can often be inflicted by certain experimental procedures. Welfare monitoring was 
performed daily for the entire duration of an experiment to ensure that the mice did not 
undergo any distress: this included monitoring social behaviour, physical appearance and 
weight. The experimental procedures performed are described in detail in section 2.9.; they 
were expected to produce only mild discomfort. Figure 3.5. shows a representative figure of 
the weights of mice taken daily during an experiment, grouped depending on the HPV16-PsVs 
dose received. Four days prior to cervicovaginal challenge with HPV16-PsVs, mice were 
injected with Depo-Provera s.c. (as indicated by the first arrow at day -4) and this had no 
effect on weight. On the day of cervicovaginal challenge, mice were lightly anaesthetised 
twice (once before N-9 treatment and again before HPV16-PsVs infection), which caused a 
slight decrease in weight. Weights then increased again on day 2 and 3, showing that the 
anaesthetic and cervicovaginal challenge had no adverse effect on welfare. Furthermore, 





Figure 3.5: Weights of C57BL/6 mice do not fluctuate significantly during an HPV16-PsVs infection 
experiment. 6-10 weeks old female wildtype C57BL/6 mice were injected with 2mg/20mL Depo-Provera 
(s.c.), followed 4 days later by pre-treatment with 25μl 4% N-9 in 3% CMC i.vag. for 6 hours prior to HPV16-
PsVs infection. Four mice per group were i.vag. infected with increasing doses of the viral particles as 
indicated. Weights of the mice were measured daily as part of their welfare monitoring. Points depict mean 
values, with error bars showing SEM. 
 
 
3.2.2. Establishing optimal infectious doses of HPV16-PsVs for in vivo infection of 
C57BL/6 mice  
 
While the protocol developed by Roberts et al. described the conditions for HPV16-PsVs 
infection of BALB/cAnNCr mice, optimal HPV16-PsVs doses for infection of C57BL/6 mice had 
to be determined. This was done using three increasing doses of HPV16-PsVs, of which the 
lowest dose of 0.4µg (approximately 1.2 x 1010 infectious units1) closely corresponded to that 
used by Roberts et al. (5 x 109 infectious units). HPV16-PsVs was delivered in 3% CMC i.vag., 
and infection was measured by firefly luciferase assays 72 hours later using homogenised 
genital tract tissue and vaginal lavages (see section 2.9.1.1). Figure 3.6.A. shows a dose-
dependent increase in HPV16-PsVs infection in the homogenised genital tract tissue. As firefly 
luciferase is transcribed and translated as an intracellular protein, one would not expect any 
luciferase activity in vaginal lavages. However, in our experiments cell lysis buffer was added 
                                                                 
1 1ng L1 protein = 3 x 107 infectious units [134] 
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to harvested lavages in order to lyse any shed cells, and therefore luciferase activity could 
also be measured in the lavages (Figure 3.6.B.). The pattern of luciferase activity measured in 
vaginal lavages was comparable to those measured in homogenised genital tract tissue which 
showed a dose-dependent increase (Figure 3.6.A.); this indicated that both vaginal lavages 
and genital tract homogenates could be used to quantify infection. The experiments  
presented in Figure 3.6.A. and B. indicate that infection with 3µg HPV16-PsVs per mouse 
resulted in the highest luciferase activity which is an index for the highest infection, and 




Figure 3.6: C57BL/6 mice exhibit a dose-dependent increase in HPV16-PsVs infectivity. 6-10 weeks old 
female wildtype C57BL/6 mice were pre-treated and infected as described in Figure 2.2. After 72 hours, 
vaginal lavages were performed and genital tracts harvested for analysis. Firefly luciferase activity was 
measured in (A) homogenised genital tract tissue and (B) vaginal lavage fluid. Data were normalised to total 
protein concentrations in the samples and are presented as x-fold to average control (no HPV16-PsVs) which 
was set as 1. Figures show quantification of one experiment, with four mice per viral dose. Statistical 
significance was determined using one-way ANOVA and Tukey post-hoc tests. *= p<0.05. Bars depict mean 








3.2.3. Optimising duration of HPV16-PsVs in vivo infection and infectious read-out 
 
In order to determine optimal infectious conditions, time course experiments are typically 
performed. Ideally, infection is tracked by detecting firefly luciferase using in vivo imaging 
systems. If these systems are unavailable, the usage of HPV16-PsVs encapsidating the 
reporter plasmid for Gaussia luciferase has been reported as a more accessible alternative 
[123]. As mentioned in section 2.3, Gaussia luciferase has a signal peptide for secretion and 
thus, luciferase activity can be measured daily from vaginal lavages of the same mouse 
without needing to euthanise the animal to dissect and homogenise the genital tract. 
Moreover, Gaussia luciferase can be measured directly from the lavages without the need for 
lysis of any shed cells as done to determine firefly luciferase (see section 3.2.2.), thereby 
potentially decreasing variations between time points. 
Infection of C57BL/6 mice with GLuc HPV16-PsVs was done in parallel to infection using FLuc 
HPV16-PsVs, in order to compare which reporter system was most suitable for time course 
experiments. Figure 3.7.A. and B. show Fluc and GLuc luciferase activity from daily vaginal 
lavages, respectively. Mice infected with GLuc HPV16-PsVs exhibited at least 10-fold higher 
luciferase readings as compared to FLuc HPV16-PsVs infected mice. This was particularly 
notable already 24 hours p.i. Furthermore, a gradual increase in GLuc activity was noted over 
time, whilst this was not seen when using FLuc.  
At the end of the experiment (72 hours p.i.), genital tract tissue from uninfected, FLuc HPV16-
PsVs infected and GLuc HPV16-PsVs infected mice was analysed for luciferase activity (Figure 
3.7.C.). As expected, mice infected with FLuc HPV16-PsVs had higher luciferase activity 
measured here compared to Gluc HPV16-PsVs infected mice, as firefly luciferase is an 
intracellular protein. Therefore, GLuc HPV16-PsVs is ideal for time course experiments, but 
when analysing genital tract tissue for luciferase activity, FLuc HPV16-PsVs is better suited.  




Figure 3.7: Comparison of firefly and Gaussia luciferase as HPV16-PsVs encapsidated reporter genes in 
time course experiments. 6-10 weeks old C57BL/6 mice were challenged with 3µg HPV16-PsVs (either 
containing FLuc or GLuc reporter plasmids) as described in Figure 2.2. Mice were lavaged with 50µL sterile 
PBS daily. A) Firefly luciferase activity measured in the vaginal lavages of uninfected versus HPV16 -PsVs 
infected mice. B) Gaussia luciferase activity measured in the vaginal lavages of uninfected versus infected 
mice. C) Comparison of luciferase activity measured in genital tract tissue homogenates after infection with 
FLuc HPV16-PsVs or GLuc HPV16-PsVs after 72 hours. Two independent experiments with four mice per 




3.3. Determining the effect of SP-A on HPV16-PsVs infection in vivo 
 
After the successful establishment of the in vivo HPV16-PsVs challenge model at UCT, various 
scientific questions can be addressed which will be extremely useful for all current and future 
studies in the laboratory. Of particularly interest and in the context of this MSc project, the 
role of SP-A for HPV infection was determined. 
 
3.3.1. SP-A is not expressed in the genital tract or vaginal lavage of naïve C57BL/6 
mice 
 
Before determining the effect of SP-A on HPV16-PsVs infection in vivo, it was important to 
first establish whether SP-A was expressed in naïve C57BL/6 mice. As described in section 
1.2.3, SP-A is expressed in the female genital tract of humans, but to our knowledge it was 
unknown whether SP-A is expressed in the female genital tract of C57BL/6 mice. Therefore, 
Western Blotting was performed (Figure 3.8.), probing for SP-A in the lung and 
bronchoalveolar lavage (BAL) (representing the positive controls), as well as the genital tract 
tissue (GT) and vaginal lavage fluid (vag. lavage). Purified human SP-A was also included as a 
positive control. It was noted that bands corresponding to SP-A protein could be detected in 
the lung and BAL, but SP-A was not detected in the genital tract or vaginal lavage of naïve 










Figure 3.8: SP-A expression in various organs and body fluids of naïve female wildtype C57BL/6 mice. Shown 
is a Western Blot probed with an antibody for murine SP-A in the lung, bronchoalveolar lavage fluid (BAL), genital 
tract tissue (GT), and vaginal lavage (vag. lavage) fluid. Tissue and lavages were taken from 6-10 weeks old female 
C57BL/6 mice that were not exposed to any HPV16-PsVs. 20µg of each sample was loaded per lane, while 0.5µg 
of purified human SP-A protein was loaded as control. No endogenous SP-A was detected in the female genital 
tract. Ponceau staining was performed to assure for equal loading (not shown).  
 
3.3.2. HPV16-PsVs infection of C57BL/6 mice does not affect SP-A expression  
  
Although SP-A could not be detected on the protein level in the genital tract of naïve mice 
(Figure 3.8.), it was possible that exposure to HPV16-PsVs would induce SP-A expression. 
Therefore, RT-PCR and Western Blot experiments were performed in order to determine 
whether cervicovaginal challenge with HPV16-PsVs induced SP-A expression in the female 
genital tract of C57BL/6 mice. 
Figure 3.9.A. shows a RT-PCR of four mice per group either uninfected or infected with HPV16-
PsVs for 24 hours: amplification of the pGL3 plasmid encapsidated by HPV16-PsVs could be 
detected in RNA extracted from the genital tract tissue of infected mice.  Analysis of SP-A gene 
expression by RT-PCR showed that SP-A mRNA was not expressed in uninfected genital tract 
tissue, nor was SP-A mRNA expression induced following infection for 24 hours (Figure 3.9.B.).  
Lung mRNA was used as a positive control for SP-A expression and Gapdh was used as a 
reference gene. Furthermore, SP-A protein expression was analysed 24 and 72 hours p.i. in 
the vaginal lavages and genital tract tissue (Figure 3.10.). Again, no SP-A protein could be 
detected. Therefore, infection with HPV16-PsVs does not affect SP-A expression in the female 






Figure 3.9: Infection of C57BL/6 mice with HPV16-PsVs does not alter SP-A mRNA expression. 6-10 weeks old 
female wildtype C57BL/6 mice were pre-treated as described in Figure 2.2. Four mice per group were i.vag. 
infected with 3µg HPV16-PsVs. Genital tract tissue was harvested 24 hours later and RNA extracted for gene 
expression analysis. A) RT-PCR of RNA from genital tract tissue to show successful infection. Amplification of the 
pGL3 plasmid was used as a positive control and H2O as a negative control. B) RT-PCR of RNA from genital tract 
tissue showing no change in SP-A expression. Lung RNA was used as a positive control and H2O as a negative 






Figure 3.10: Infection of C57BL/6 mice with HPV16-PsVs does not alter expression of SP-A. 6-10 weeks old 
female wildtype C57BL/6 mice per group were pre-treated as described in Figure 2.2. Four mice per group were 
i.vag. infected with 3µg HPV16-PsVs. Vaginal lavages were performed 24 and 72 hours  p.i. and genital tract tissue 
was harvested 24 hours or 72 hours p.i. Western Blots of vaginal lavage fluid (top panel) and homogenised 
genital tract tissue (bottom panel) were probed for the presence of SP-A. 20µg of each sample was loaded per 
lane, while 0.5µg purified human SP-A protein was loaded as control. *Loading control corresponds to a 45kDa 







3.3.3. SP-A reduces HPV16-PsVs infection in C57BL/6 mice 
 
In order to assess any effect of SP-A on HPV16-PsVs infection in vivo, 1:1 and 1:10 (w/w) 
HPV16-PsVs to SP-A ratios were tested (shown in Figure 3.11. as 3µg and 30µg SP-A, 
respectively). Figure 3.11. shows that 30µg SP-A reduced HPV16-PsVs infection, as measured 
in the vaginal lavage (left panel) and genital tract tissue (right panel). Although this was not 
deemed to be significant, a clear trend can be seen in luciferase activity measured in the 
lavages as well as genital tract tissue, with 30µg SP-A reducing HPV16-PsVs approximately 4-
fold. From this experiment, a 1:10 HPV16-PsVs to SP-A ratio (30µg SP-A) was chosen as the 
optimal amount of SP-A to be used in further experiments. This ratio also corresponded to in 
vitro experiments involving RAW264.7 macrophages, where 0.5µg HPV16-PsVs was pre-
incubated with 5µg SP-A (Figure 3.2.D.). Pre-incubation of SP-A and HPV16-PsVs was done in 
the absence of calcium for all in vivo experiments, as preliminary experiments showed that 
addition of calcium here had no effect on infection (Supplementary Figure 5). Calcium would 
have been present in the genital tract, which may explain why no difference was seen in the 
presence of additional calcium. 
Based on the conditions described in Figure 3.11.A, further experiments determining the 
effect of SP-A on HPV16-PsVs infection were performed under refined experimental settings. 
Including BSA as a control protein (see also Figure 3.2.D.), a 10-fold excess (w/w) of SP-A or 
BSA to HPV16-PsVs was used. When compared to BSA, incubation with SP-A resulted in 
approximately 4-fold reduction in HPV16-PsVs (Figure 3.11.B), which was measured as firefly 
luciferase activity in both the vaginal lavage fluid (following addition of lysis buffer to lyse 






Figure 3.11: SP-A reduces HPV16-PsVs infection in C57BL/6 mice. 6-10 weeks old female wildtype C57BL/6 
mice per group were pre-treated as described in Figure 2.2. A) HPV16-PsVs encapsidating firefly luciferase 
were pre-incubated with two increasing amounts of purified SP-A protein for 1 hour on ice. B) 3µg HPV16-
PsVs were pre-incubated with 30µg purified SP-A protein or 30µg BSA for 1 hour on ice.  Mice were 
euthanised 72 hours p.i., and tissue harvested for analysis. Firefly luciferase activity was measured in vaginal 
lavage fluid (left panels) and homogenised genital tract tissue (right panel s). Data were normalised to total 
protein in the samples and are presented as x-fold to average control (no SP-A) which was set as 1. Figure 
A shows the data from one experiment with four mice per condition. Figure B shows pooled data from two 









Time course experiments were performed to further assess the effect of SP-A on HPV16-PsVs 
infection over 72 hours. This was achieved using GLuc HPV16-PsVs and measuring luciferase 
activity from vaginal lavages which were performed daily. Figure 3.12. shows luciferase 
activity measured over 72 hours from mice infected with GLuc HPV16-PsVs pre-incubated 
with a 10-fold (w/w) excess of either 30µg BSA or 30µg SP-A. It was seen that pre-incubation 
with SP-A reduced infection as compared to the control, and this effect was most prominent 
after 24 hours (4-fold decrease in infection). After 48 and 72 hours, SP-A decreased infection 
by 1.5-fold, showing that SP-A is most protective in the very early stages of infection. Although 




Figure 3.12: SP-A-mediated reduction of HPV16-PsVs infection is maximal at 24 hours p.i. 6-10 weeks old 
C57BL/6 mice were challenged with 3µg HPV16-PsVs (containing the GLuc reporter plasmid), either pre-
incubated with 30µg BSA (control) or 30µg SP-A, following the procedure described in Figure 2.2. Mice were 
lavaged with 50µL sterile PBS daily over 72 hours, and luciferase activity measured. Relative luciferase 
activity (R.L.U) represents luminescence (arbitrary units) divided by protein concentration (mg/mL).  Shown 





3.3.4. The presence of SP-A does not affect macrophage recruitment in the genital 
tract of C57BL/6 mice 
 
To determine whether pre-incubation of AF488-HPV16-PsVs with SP-A influenced 
macrophage recruitment in the genital tract, IHC followed by confocal microscopy was used. 
Genital tract tissue was excised 24 hours p.i., as the SP-A-mediated reduction in infection was 
most pronounced after 24 hours (Figure 3.12.). The left panel of Figure 3.13.A. shows that 
there was no clear difference in macrophage recruitment in the epithelium after 24 hours for 
each condition tested. This was supported by quantification of the area of F4/80 macrophage 
staining (Figure 3.13.B.), which showed no significant difference in the area occupied by 
macrophages for each condition. Furthermore, under the chosen conditions AF488-HPV16-
PsVs could not be detected in the genital tract tissue, but successful infection was validated 





Figure 3.13: The presence of SP-A does not alter macrophage recruitment during HPV16-PsVs infection. 
6-10 weeks old C57BL/6 mice were challenged with 3µg AF488-HPV16-PsVs either pre-incubated with 30µg 
BSA (control) or 30µg SP-A, following the procedure described in Figure 2.2. Genital tract tissue was excised, 
embedded in OCT and cryosectioned, followed by staining with F4/80 antibody and Hoechst nuclear stain. 
A) Representative maximum intensity projections of F4/80 (left panel) and IgG2B isotype control (right 
panel) for no HPV16-PsVs, HPV16-PsVs and BSA and HPV16-PsVs and SP-A. B) Bar graph showing the average 
percentage area of F4/80 positive staining in the epithelium for each condition, using 10 maximum intensity 






HPV successfully manages to evade the host immune response which can result in persistent 
infections and ultimately cancer development, with cervical cancer being the predominant 
HPV-associated malignancy. The majority of cervical cancer cases occur in the developing 
world, where the high incidence of HIV/AIDS is known to exacerbate these cases [130].  
Although highly efficient prophylactic vaccines exist to prevent HPV16 and HPV18 infection, 
these are largely unavailable in low-resource settings due to the high costs involved and the 
requirement for one or two repeat vaccinations (depending on the age of first vaccination). 
Moreover, they do not cover all the oncogenic HPV types, and the extent of cross-protection 
against other oncogenic HPV types is largely unknown. This is specifically relevant in sub-
Saharan Africa, where oncogenic HPV35 and 45 are highly prevalent due to their association 
with changes in immunodeficiency levels [131]. Fortunately, there are some pilot state-
funded school-based vaccination projects underway to immunise adolescent girls in South 
Africa [45]. Nevertheless, it is expected that high-risk HPV will remain responsible for 
substantial disease burden for decades.  
Studying means to enhance the innate immune recognition of the virus may, in the long term, 
lead to the development of alternative cost-effective, broad-spectrum approaches to 
preventing HPV infection. To this end, this research focused on the innate immune proteins 
SP-A and SP-D as potential candidates to impact HPV infection, as these molecules are known 
to enhance clearance of various viral and bacterial pathogens in the lung as well  as other sites 
of the body [58]. As proof of concept, this study was limited to pseudovirions of HPV type 16, 
representing the most common oncogenic HPV type globally. Initially, in vitro experiments on 
the impact of surfactant proteins on HPV16-PsVs infection were performed, which were then 






4.1. The interaction of SP-A with HPV16-PsVs and the functional consequences in 
vitro 
 
In order to determine whether SP-A and/or SP-D bind to HPV16-PsVs, Co-IP experiments were 
performed. It was observed that SP-A, but not SP-D, could bind to HPV16-PsVs (Figure 3.2. B-
C). Since SP-A and SP-D often act as opsonins by binding to certain pathogens, these 
experiments gave the first indication that SP-A, but not SP-D, may have a potential role in 
recognising HPV16-PsVs. This was further supported when the functional consequences of 
this binding were analysed by examining viral internalisation by RAW264.7 macrophages in 
the presence of either SP-A or SP-D: indeed, it was observed that SP-A enhanced viral 
internalisation, while SP-D had no effect (Figure 3.2.D.). This further supported the hypothesis 
that SP-A may opsonise HPV16-PsVs, thereby increasing immune cell recognition of the virus 
and viral clearance. It is important to note that HPV16-PsVs infection, i.e. the arrival in the 
nucleus and successful transcription of the reporter gene luciferase (encapsidated in the viral 
particle representing the pseudogenome), was extremely low in RAW264.7 macrophages 
compared to the luciferase activity measured in the epithelial cell line HeLa, whose infectivity 
was not affected by SP-A (Figure 3.2.E). This is supported by the general assumption that HPV 
has a very strict tissue tropism in vivo and exclusively infects basal epithelial cells, as its life 
cycle is dependent on the differentiation of basal cells into keratinocytes. While macrophages 
are not known to be infected by HPV, the data presented herein indicate that they can 
internalise (and probably “kill”) the virus reducing its potential to infect epithelia l cells, which 
was enhanced in the presence of SP-A. This molecule therefore presented an interesting 
candidate for further study in terms of enhancing immune recognition of HPV, thereby 
preventing infection.  
 When the mode of SP-A-mediated increase in viral internalisation by RAW264.7 
macrophages was further studied, it was observed that this interaction was calcium- but not 
mannose-dependent. Previous crystallographic and solution binding studies have elucidated 
the calcium binding sites of SP-A: one site is located in the CRD, whilst another site is located 
in an anionic portion of the neck region [67]. It is likely that the calcium binding site in the 
neck region is important in the context of HPV16-PsVs, as the CRD seems to not be involved 
in binding and increased viral internalisation as revealed by the competition studies using 
mannose (Figure 3.4.). The non-involvement of SP-A’s CRD in binding to HPV16-PsVs is not 
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surprising as HPV is not known to display glycosylated surface/capsid proteins. SP-A may 
instead recognise HPV16-PsVs in an alternate manner, such as via the neck domain. Further 
studies are needed to confirm this hypothesis, for example by using recombinant fragments 
of SP-A and determining which portion of the protein interacts with the virus.  
 
4.2. Establishment of the HPV16-PsVs murine challenge model at UCT 
 
The in vitro results described above supported the hypothesis that SP-A may opsonise HPV16-
PsVs, thereby increasing viral recognition by immune cells such as macrophages, leading to 
viral clearance and decreased infection. While cell culture experiments were valuable in 
initially studying the interaction between SP-A and HPV16-PsVs, they cannot sufficiently 
recapitulate the early events of sexual HPV transmission. The site of natural infection, i.e. the 
female genital tract, is very complex as several diverse cell types are potentially involved in 
infection as well as immune responses upon challenge with oncogenic HPV, including local 
epithelial cells and recruitment of inflammatory cells.  
 
To study the described in vitro findings further, in vivo studies are not only appropriate to 
confirm these observations but also to identify underlying mechanisms  which contribute to 
the SP-A and HPV16-PsVs relationship. To this end, an HPV16-PsVs murine cervicovaginal 
challenge model, which is being widely used in the field, was set up at UCT as part of this MSc 
project. This model was developed by Roberts et al. [122] in 2007 as the first animal model to 
recapitulate the early events of human sexual transmission of HPV infecting the 
cervicovaginal epithelium.  While productive papillomavirus infection with authentic vi rions 
is difficult and highly species- and tissue-restricted, HPV pseudovirions can transduce murine 
genital epithelium under the specific conditions developed by Roberts et al. [122]. These 
conditions include progesterone treatment for four days, abrasion of the genital tract 
immediately before exposure to the pseudovirus, and tissue analysis for reporter gene 
expression 72 hours after inoculation. Very recently, a murine papillomavirus mouse model 
has been developed [121] which allows the study of anogenital disease and cancers 
associated with papillomaviruses, rather than early (non-productive) events as described in 
this thesis. However, since all in vitro experiments were performed using HPV16-PsVs, it was 
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ideal to continue using these same particles  together with the in vivo model described by 
Roberts et al. [122].  
With the aim to study the effect of SP-A on HPV16-PsVs infection in vivo, various experimental 
parameters had to be optimised. For this study, C57BL/6 mice instead of BALB/cAnNCr mice 
(as per the protocol by Roberts et al.[122]) were used for HPV16-PsVs challenge experiments, 
because SP-A knockout mice were available in this strain to be used in future studies. Firstly, 
the optimal HPV16-PsVs dose was determined as 3µg HPV16-PsVs (9 x 1010 infectious units) 
per mouse (Figure 3.6.), which was a higher dose than that described by Roberts et al. (5 x 
109 infectious units). This could be explained by the different mouse strain used as well as 
different technical approaches to assess infection: since no live imaging system was available 
to measure luminescence, readings were obtained using homogenised genital tract tissue as 
well as vaginal lavages. Both firefly and Gaussia luciferase resulted in comparable patterns of 
infection. While Gaussia luciferase (being a secreted enzyme) was highly detectable in the 
vaginal lavages, some firefly luciferase (although being primarily an intracellular enzyme) was 
also detected in the lavages, probably due to the release of the enzyme from shed cells 
following the addition of a cell lysis buffer. Overall, it was found that depending on the 
experimental read-out, either firefly or Gaussia luciferase could be reliably used. For example, 
for time course experiments, GLuc-containing HPV16-PsVs was deemed to be more suitable 
than FLuc HPV16-PsVs. Using GLuc-HPV16-PsVs allowed for luciferase activity to be measured 
daily, as Gaussia luciferase was secreted and no cell lysis buffer was needed (Figure 3.7.). 
While firefly luciferase activity could also be measured in lavages from FLuc-HPV16-PsVs, 
these values were at least 10-fold lower than when using GLuc-HPV16-PsVs, and they did not 
increase over the 72-hour time-course (Figure 3.7.). Therefore, GLuc-HPV16-PsVs was better 
suited for time course experiments.  
It is important to note that the HPV16-PsVs murine challenge model used here did not cause 
distress, as procedures were mild and did not negatively affect the well-being of the mice. 
Mice did not develop any pathologies because the model used pseudovirions only carrying a 
reporter gene, and the model was designed to study early stages of infection running over a 
very short period of seven days. Now that this HPV16-PsVs murine challenge model has been 
established at UCT, it will prove to be an invaluable tool in our laboratory to study other 
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modulators of HPV16 infection in vivo such as the recently identified HPV-restriction molecule 
vimentin [126].  
 
4.3. SP-A expression in the murine genital tract and its impact on HPV16-PsVs 
infection in vivo 
 
Before the effect of SP-A on HPV16-PsVs infection could be studied in vivo, it was necessary 
to determine endogenous SP-A expression in naïve and HPV-infected animals. While SP-A 
expression in the human female genital tract has been described previously [101], to our 
knowledge it was unknown whether SP-A was expressed in the murine female genital tract. 
Therefore, SP-A protein expression was initially analysed in naïve C57BL/6 mice prior to 
HPV16-PsVs challenge experiments. No endogenous SP-A could be detected in the vaginal 
lavages or the genital tract tissue of naïve C57BL/6 mice while it was abundantly present in 
the lung and alveolar lavage fluid as expected (Figure 3.8.). Next, the effect of HPV16-PsVs 
challenge on induction of endogenous SP-A expression was to be determined. Various studies 
have described the upregulation of SP-A following infection with certain pathogens (such as 
Klebsiella pneumoniae [132]), with the increase in expression suggested to have a protective 
effect against infection. In the Swiss Black murine female genital tract, SP-D has been shown 
to be upregulated following infection with C.muridarum [108]. However, no SP-A expression 
was observed following HPV16-PsVs infection, neither on mRNA level nor on protein level 
(Figure 3.9. and Figure 3.10.).  
The absence of SP-A in the genital tract of C57BL/6 mice made the use of SP-A knockout mice 
become obsolete. Instead of studying a loss-of-function approach to determine whether mice 
deficient in SP-A were more susceptible to incoming HPV virions as initially planned, the focus 
of this project was shifted to the question whether artificial supplementation with exogenous 
SP-A had an effect on HPV challenge. 
To this end, HPV16-PsVs were pre-incubated with purified SP-A protein before inoculation 
into the female C57BL/6 murine genital tract. As seen already in cell culture, the 1:10 HPV16-
PsVs to SP-A (w/w) ratio, which caused the largest increase in HPV16-PsVs internalisation by 
RAW264.7 macrophages, also caused the most substantial decrease in HPV16-PsVs infection 
in vivo (Figure 3.11). This observation supported the hypothesis that SP-A may facilitate HPV 
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recognition by immune cells leading to an overall decrease in infection of epithelial cells. 
While these results were not significant, a definite trend was seen for each individual 
experiment performed. When studied over 72 hours, it was noted that the most substantial 
decrease in infection was 24 hours p.i. (Figure 3.12). This could be explained by SP-A being an 
innate immune protein, thereby typically exerting its protective effects early during an 
infection.  
Since it was hypothesised that macrophages were likely to be involved in the SP-A-mediated 
reduction of HPV16-PsVs infection, macrophage recruitment was studied using IHC and 
confocal microscopy. Our results indicated that SP-A had no effect on macrophage 
recruitment during infection with HPV16-PsVs after 24 hours (Figure 3.13.). Furthermore, 
although successful infection was confirmed using vaginal lavages, the AF488 labelled HPV16-
PsVs particles could not be detected in infected genital tract tissue after this period. These 
results may not be an accurate reflection of what may be occurring in the genital tract after 
HPV16-PsVs infection, for a number of reasons. Firstly, the time point chosen for genital tract 
extraction (24 hours p.i.) may have been unsuitable for visualising HPV16-PsVs infection. This 
time point was chosen as SP-A had the most substantial effect on HPV16-PsVs by reducing 
infection by 4-fold 24 hours p.i. (Figure 3.12.); however, Roberts et al. examined tissue 2 hours  
p.i. and AF488-HPV16-PsVs was detectable [122]. After 24 hours, it was likely that capsid 
degradation had already occurred, or the fluorescent AF488 signal may have been bleached. 
Secondly, the usage of N-9 to chemically disrupt the genital epithelium may have been 
unsuitable for macrophage recruitment experiments. Although disruption of the genital 
epithelium is absolutely required for successful HPV infection, both in this mouse model as 
well as in the natural setting, N-9 is transiently proinflammatory [133]. It is therefore plausible 
that any effect on macrophage recruitment due to SP-A and/or HPV16-PsVs infection would 
have been masked. In future experiments, it may be more suitable to use a cytobrush to 
mechanically disrupt the genital epithelium, which may more appropriately mimic the natural 
process. This might also explain why the effect of SP-A on HPV infection compared to controls 
did not reach statistical significance; N-9 mediated inflammation and macrophage 
recruitment might have concealed underlying effects. Thirdly, the technique used to analyse 
macrophage recruitment also has its limitations: because the area was measured from a 2-
dimensional maximum intensity projection, it did not account for any macrophages which 
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may have overlapped those found in different layers of the tissue section. While cell  counting 
was an alternative option, this method is more biased than measuring the area occupied and 
it does not account for changes in macrophage complexity or size due to activation. In the 
future, it may be beneficial to study different immune cells, such as Langerhans cells. 
Additionally, the inflammatory response following inflammation can be measured by 
analysing cytokine responses. 
Therefore, although the HPV16-PsVs murine challenge model described here is widely used 
in the field to address various HPV-related research questions, it may be unsuitable for 
studying innate immune responses in the murine female genital tract, and some optimisation 
is required in future studies, such as alternative epithelial cell disruption techniques, 
alternative time points for read-outs and alternative immune markers to study. This would 
allow for more insight on the mechanism by which SP-A reduces HPV16-PsVs infection. 
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5. Conclusion  
 
In this study, it was aimed to determine whether surfactant proteins A and D enhanced the 
immune recognition of HPV16-PsVs in the female genital tract, thereby preventing new 
infection. In vitro, it was observed that SP-A interacted with HPV16-PsVs and enhanced 
uptake of the pseudovirus by RAW264.7 macrophages in a calcium-dependent and CRD 
independent manner. In the context of an in vivo HPV16-PsVs murine cervicovaginal challenge 
model, it was determined that SP-A reduced HPV16-PsVs infection in female C57BL/6 mice. 
Although some optimisation is still required, the set-up of the HPV16-PsVs challenge model 
at UCT will open new doors to address several HPV-related research questions in vivo. As 
exemplified by this study, the impact of HPV-binding molecules potentially inhibiting infection 
can be studied. In the long term, once the correct region of SP-A which binds to HPV16-PsVs 
has been identified, analogues or recombinant fragments of SP-A could be incorporated into 
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Composition of solutions used 
 
Complete medium: Dulbecco’s Modified Eagle Medium (DMEM), 10% foetal calf serum 
(FCS) (Biochrom), Penicillin (100 U/mL) and Streptomycin (100 mg/mL).  
 
SDS-PAGE Separating gel 10%: 1.5M Tris-HCl, pH 8.8; 10% (w/v) SDS; 40% acrylamide; 10% 
(w/v) ammonium persulphate; 0.01% tetramethylethylenediamine (TEMED).  
 
SDS-PAGE Stacking gel 3%: 1M Tris-HCl, pH 6.8; 10% (w/v) SDS; 40% Acrylamide; 10% (w/v) 
ammonium persulphate; 0.01% TEMED. 
 
10X SDS-PAGE running buffer: 30g solid Tris; 144g solid glycine; 10g SDS powder; add dH2O 
to 1L. This stock solution was diluted 10-fold before use. 
 
5X reducing protein loading buffer: 10µL 1M DTT in 90µL 5X Non-Reducing Lane Marker 
(Thermo Scientific).  
 
10X Tris-Glycine transfer buffer: 30.3g Tris base; 144g glycine; add dH2O to 1L. 
 
1 X Tris-Glycine transfer buffer: 100mL 10X Tris-Glycine transfer buffer; 200mL methanol; 
add dH2O to 1L. 
 
Ponceau S stain: 0.2% Ponceau S, 5% acetic acid.  
 




Harsh stripping solution: 8.75mL 8M guanidinium chloride; 200µL Tris-HCl pH 7.4; 50µL 2M 
DTT; 1mL dH2O.  
 
TE buffer: 10mM Tris-HCl; 1mM EDTA, pH 8.0.  
 
2X HBS buffer: 50mM HEPES; 280mM NaCl; 1.5mM Na2HPO4, pH 7.1. Filter sterilised.  
 
5X HSB buffer: 125mM HEPES; 2.5M NaCl; 0.1% Brij58; 5mM MgCl2; 500µM EDTA; 2.5% 
ethanol; filter sterilised.   
 
Light CsCl: 54g CsCl in 200mL 1xHSB buffer, filter sterilised. 
 
Heavy CsCl: 77.6g CsCl in 200mL 1xHSB buffer, filter sterilised.  
 
FACS wash: 0.5% BSA in PBS, opt. 5mM EDTA, 2mM NaN3. 
 
FACS fix: 1% (v/v) formaldehyde in FACS wash. 
 
50X TAE buffer: 242 g Tris, 57.1 mL glacial acetic acid, 100 mL 0.5 M EDTA (pH 8.0), made up 
to 1L with dH2O. 
 
6X DNA loading dye: 3.75mL 30% glycerol, 25mg bromophenol blue 0.25%, dH2O to 10mL.  
 





















Supplementary Figure 1: Flow cytometry analysis of RAW264.7 cell population using a dot plot of FSC versus 






Supplementary Figure 2: Example of selecting epithelium for macrophage area calculations. Epithelial tissue 
was selected manually using the transmitted light and Hoechst channels to determine epithelial structure. The 
area of F4/80 staining in the epithelium was then quantified by setting the lower and upper thresholds at 18 and 








Supplementary Figure 3: Pilot experiments determined that 5µg SP-A (10-fold excess w/w) enhances viral 
uptake by RAW264.7 macrophages. RAW264.7 cells were infected with (A) No AF488-HPV16-PsVs and (B) 
AF488-HPV16-PsVs only (0.5µg) as experimental controls. 0.5µg AF488-HPV16-PsVs were also pre-incubated 
with either (C) 1μg or (D) 5μg SP-A for 1 hour prior to incubation with RAW264.7 cells . Fluorescence in the FL1 
channel was plotted against side scatter (SSC). Values in the lower right (LR) quadrant indicate the percentage 




Supplementary Figure 4: Representative dot plots showing AF488-HPV16-PsVs internalisation by RAW264.7 
macrophages. Fluorescence was measured in the FL1 channel and plotted against side scatter for (A) no AF488 -
HPV16-PsVs, (B) AF488-HPV16-PsVs only, (C) AF488-HPV16-PsVs and 5µg SP-A, (D) AF488-HPV16-PsVs and 5µg 
SP-D, (E) AF488-HPV16-PsVs and 5µg BSA, (F) SP-A only. Values in the lower right (LR) quadrant indicate the 






Supplementary Figure 5: Addition of calcium has no effect on SP-A-mediated reduction of HPV16-PsVs 
infection in vivo. 3µg HPV16-PsVs were pre-incubated with 30µg purified SP-A protein or 30µg SP-A and 
5mM CaCl2 for 1 hour on ice. Mice were then infected with these pre-incubated HPV16-PsVs particles. Mice 
were euthanised 24 hours p.i., and tissue harvested for analysis. Firefly luciferase activity was measured in 
vaginal lavage fluid (left panels) and homogenised genital tract tissue (right panel s). Data were normalised 
to total protein in the samples and are presented as x-fold to average control (no SP-A) which was set as 1.  
 
 
